Ticker,Name,Market_Cap,Volume,Beta,Daily Volatility,Latest Share Price,Insiders_Buying,Institutions_Buying,Stage,Sector,Industry,Drug_Name,FDA-Approved_Drug/Drugs,FDA_Fast_Track_Designations,Catalysts_Date,Partners,Space,Competitors,Cash_Runway,Last_Earnings_Date,Last_Earnings_Result,Next_Earnings_Date,Rating,SA_Rating,Country,Comments
ABCL,AbCellera Biologics Inc.,730M,1.5M,2.13,2.5% - 7%,$2.49 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,ABCL-001 ABCL-002,None,None,Phase 1 Data Readout Q4 2025,Lilly (LLY) Pfizer (PFE),Antibody Discovery,Amgen (AMGN) Regeneron (REGN),24 months,May 7 2025,EPS -0.14 -6% Miss Revenue 9.8M -10% Miss,Aug 5 2025 (est.),6 (B),HOLD,Canada,Trading below cash value; strong partnerships; pipeline advancing but revenue growth limited[](https://x.com/Hedgebullish/status/1932116713451209027)[](https://x.com/brooks_david3/status/1930461578958106742)[](https://x.com/GVDInvestor/status/1932436001764339801)
ABEO,Abeona Therapeutics Inc.,210M,350K,1.89,3% - 8%,$5.12 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,EB-101 Pz-cel,None,Pz-cel Fast Track 2019,Phase 3 Data Readout Q2 2026,None,Gene Therapy,Krystal Biotech (KRYS),18 months,May 6 2025,EPS -0.45 -8% Miss Revenue 0.3M -20% Miss,Aug 4 2025 (est.),5 (B-),HOLD,USA,Limited revenue; cash runway constrained; EB-101 pivotal data critical
ABSI,Absci Corporation,450M,900K,2.45,3.5% - 9%,$4.85 - 01:30 PM EDT 06/10/2025,No,Increase,Pre-Clinical,Healthcare,Biotechnology,ABSI-101,None,None,None,AstraZeneca (AZN) Merck (MRK),AI-Driven Drug Discovery,Schrodinger (SDGR) Recursion (RXRX),20 months,May 8 2025,EPS -0.22 -5% Miss Revenue 1.8M +10% Beat,Aug 6 2025 (est.),7 (B+),BUY,USA,AI-driven platform gaining traction; early-stage pipeline; partnerships strong
ABUS,Arbutus Biopharma Corporation,650M,1.2M,1.95,2.8% - 7.5%,$3.45 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Imdusiran,None,None,Phase 2 Data Readout Q3 2026,None,HBV Therapy,Gilead (GILD) Moderna (MRNA),15 months,May 2 2025,EPS -0.12 -10% Miss Revenue 1.5M -15% Miss,Jul 31 2025 (est.),6 (B),HOLD,Canada,HBV focus; limited near-term catalysts; cash runway tight
ACAD,ACADIA Pharmaceuticals Inc.,2.8B,1.1M,1.34,2% - 6%,$15.20 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,NUPLAZID DAYBUE,NUPLAZID Apr 2016 DAYBUE Mar 2023,NUPLAZID Fast Track 2014,Phase 3 Data Readout ACP-101 Q1 2026,None,CNS Disorders,Eisai (ESALY) Biogen (BIIB),30 months,May 8 2025,EPS 0.10 +15% Beat Revenue 205.8M +8% Beat,Aug 6 2025 (est.),8 (A-),BUY,USA,Strong commercial traction with DAYBUE; pipeline expansion promising
ACET,Adicet Bio Inc.,150M,400K,1.78,3.2% - 8.5%,$1.40 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,ADI-001,None,None,Phase 1 Data Readout Q4 2025,Regeneron (REGN),Cell Therapy,Allogene (ALLO) Fate Therapeutics (FATE),12 months,May 7 2025,EPS -0.36 -12% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),5 (B-),SELL,USA,High-risk cell therapy; limited cash runway; early-stage pipeline
ACLX,Arcellx Inc.,1.9B,500K,1.65,2.5% - 7%,$55.30 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,Anito-cel,None,Anito-cel Fast Track 2023,Phase 2 Data Readout Q3 2026,Kite/Gilead (GILD),Cell Therapy,Allogene (ALLO) Caribou (CRBU),24 months,May 9 2025,EPS -0.50 -5% Miss Revenue 21.3M +12% Beat,Aug 7 2025 (est.),7 (B+),BUY,USA,Promising cell therapy pipeline; strong partnership with Gilead
ACRS,Aclaris Therapeutics Inc.,90M,600K,1.92,3% - 8%,$1.15 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,ATI-1777,None,None,Phase 2b Data Readout Q2 2026,None,Dermatology,Incyte (INCY) Dermavant,12 months,May 7 2025,EPS -0.15 -10% Miss Revenue 2.4M -8% Miss,Aug 5 2025 (est.),5 (B-),HOLD,USA,Small-cap dermatology focus; limited cash runway; pipeline early-stage
ADAP,Adaptimmune Therapeutics plc,200M,800K,2.01,3.5% - 9%,$0.85 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Aficamten,None,Aficamten Fast Track 2022,Phase 3 Data Readout Q4 2026,GSK (GSK),T-Cell Therapy,Immunocore (IMCR) TCR2,15 months,May 8 2025,EPS -0.18 -15% Miss Revenue 5.9M -10% Miss,Aug 6 2025 (est.),6 (B),HOLD,UK,High-risk T-cell therapy; cash runway constrained; GSK partnership key
ADPT,Adaptive Biotechnologies Corp.,650M,700K,1.87,2.8% - 7.5%,$3.60 - 01:30 PM EDT 06/10/2025,No,Stable,Commercial,Healthcare,Biotechnology,clonoSEQ,clonoSEQ Sep 2018,None,New Indication Data Q3 2025,Genentech (RHHBY),Immunosequencing,Illumina (ILMN) 10x Genomics (TXG),18 months,May 7 2025,EPS -0.34 -8% Miss Revenue 41.5M +5% Beat,Aug 5 2025 (est.),6 (B),HOLD,USA,clonoSEQ commercialized; diagnostic focus; stable but slow growth
ADMA,ADMA Biologics Inc.,1.2B,2.5M,1.45,2% - 6%,$10.80 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,ASCENIV BIVIGAM,ASCENIV Apr 2019 BIVIGAM Oct 2019,None,None,None,Immunology,CSL Behring (CSLLY) Grifols (GRFS),36 months,May 9 2025,EPS 0.08 +20% Beat Revenue 81.9M +10% Beat,Aug 7 2025 (est.),8 (A-),BUY,USA,Strong commercial growth; expanding manufacturing capacity; financially stable
AGEN,Agenus Inc.,250M,1.8M,1.98,3.5% - 9%,$0.65 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Botensilimab,None,None,Phase 2 Data Readout Q1 2026,BMS (BMY) Merck (MRK),Immuno-Oncology,Incyte (INCY) Regeneron (REGN),12 months,May 7 2025,EPS -0.22 -18% Miss Revenue 37.2M -5% Miss,Aug 5 2025 (est.),5 (B-),SELL,USA,High-risk immuno-oncology; cash runway tight; pipeline speculative
AGIO,Agios Pharmaceuticals Inc.,2.4B,600K,1.76,2.5% - 7%,$43.50 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,Biotechnology,PYRUKYND,PYRUKYND Feb 2022,PYRUKYND Fast Track 2020,Phase 3 Data Readout Q2 2026,Servier,Oncology,Servier Bristol Myers (BMY),24 months,May 2 2025,EPS -1.65 -10% Miss Revenue 8.2M +15% Beat,Jul 31 2025 (est.),7 (B+),BUY,USA,PYRUKYND commercialized; pipeline advancing; stable cash position
ALDX,Aldeyra Therapeutics Inc.,350M,400K,1.92,3% - 8%,$3.90 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Reproxalap,None,Reproxalap Fast Track 2019,Phase 3 Data Readout Q4 2025,None,Ophthalmology,Allergan (ABBV) Bausch (BHC),18 months,May 7 2025,EPS -0.28 -12% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Ophthalmology focus; reproxalap pivotal data key; cash runway limited
ALEC,Alector Inc.,450M,500K,1.67,2.8% - 7.5%,$5.10 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Latozinemab,None,Latozinemab Fast Track 2023,Phase 3 Data Readout Q3 2026,GSK (GSK),Neurodegenerative Diseases,Denali (DNLI) Biogen (BIIB),20 months,May 8 2025,EPS -0.45 -10% Miss Revenue 15.1M -8% Miss,Aug 6 2025 (est.),6 (B),HOLD,USA,Neuro focus; GSK partnership; early-stage pipeline
ALLO,Allogene Therapeutics Inc.,400M,900K,1.88,3.2% - 8.5%,$2.70 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Cema-cel,None,Cema-cel Fast Track 2022,Phase 2 Data Readout Q4 2026,Pfizer (PFE),Cell Therapy,Arcellx (ACLX) Kite/Gilead (GILD),18 months,May 7 2025,EPS -0.38 -7% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Allogeneic cell therapy; high-risk; Pfizer partnership key
ALNY,Alnylam Pharmaceuticals Inc.,19.5B,700K,1.23,2% - 5.5%,$152.30 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,AMVUTTRA Givlaari Oxlumo,AMVUTTRA Jun 2022 Givlaari Nov 2019 Oxlumo Nov 2020,AMVUTTRA Fast Track 2021,Phase 3 Data Readout Vutrisiran Q1 2026,Regeneron (REGN) Sanofi (SNY),RNAi Therapeutics,Arrowhead (ARWR) Ionis (IONS),36 months,May 2 2025,EPS -0.75 +5% Beat Revenue 494.7M +12% Beat,Jul 31 2025 (est.),9 (A),STRONG BUY,USA,Strong RNAi portfolio; multiple approved drugs; robust pipeline[](https://www.biopharmcatalyst.com/news/2020/argenx-argx-shares-rally-on-positive-late-stage-data-34-alnylam-alny-lumasiran-pdufa-set-for-december)
AMRX,Amneal Pharmaceuticals Inc.,2.1B,1.3M,1.45,2% - 6%,$6.95 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,Pharmaceuticals,Generic Drugs,N/A,N/A,N/A,Fosun Pharma,Generics,Teva (TEVA) Viatris (VTRS),N/A,May 8 2025,EPS 0.14 +10% Beat Revenue 659.2M +8% Beat,Aug 6 2025 (est.),7 (B+),BUY,USA,Stable generics business; limited innovation; financially sound
AKRO,Akero Therapeutics Inc.,1.8B,800K,1.78,2.8% - 7.5%,$24.50 - 01:30 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,EFX,None,EFX Fast Track 2020,Phase 3 Data Readout Q4 2026,None,NASH,Madrigal (MDGL) Intercept (ICPT),24 months,May 7 2025,EPS -0.85 -12% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),7 (B+),BUY,USA,NASH focus; EFX pivotal data critical; strong cash position
ANAB,AnaptysBio Inc.,650M,300K,1.65,2.5% - 7%,$24.80 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Clinical,Healthcare,Biotechnology,Rosnilimab,None,None,Phase 2 Data Readout Q2 2026,GSK (GSK),Immunology,Regeneron (REGN) Amgen (AMGN),18 months,May 9 2025,EPS -1.60 -15% Miss Revenue 10.4M -10% Miss,Aug 7 2025 (est.),6 (B),HOLD,USA,Immunology pipeline; GSK partnership; moderate risk
ANVS,Annovis Bio Inc.,120M,1.2M,2.10,4% - 10%,$6.50 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Buntanetap,None,Buntanetap Fast Track 2023,Phase 3 Data Readout Q3 2026,None,Neurodegenerative Diseases,Alector (ALEC) Denali (DNLI),12 months,May 7 2025,EPS -0.95 -20% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),5 (B-),SELL,USA,High-risk neuro focus; limited cash runway; early-stage pipeline[](https://finance.yahoo.com/quote/ANVS/)
APLS,Apellis Pharmaceuticals Inc.,4.8B,1.1M,1.54,2% - 6%,$40.20 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,SYOVRE Empaveli,SYOVRE Feb 2023 Empaveli May 2021,SYOVRE Fast Track 2022,Phase 3 Data Readout Q1 2026,Swedish Orphan (SOBI),Ophthalmology,Regeneron (REGN) Roche (RHHBY),30 months,May 7 2025,EPS -0.55 +8% Beat Revenue 162.5M +10% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,Strong commercial traction with SYOVRE; pipeline expanding
ARCT,Arbutus Biopharma Corp.,450M,600K,1.92,3% - 8%,$3.10 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,ARCT-810,None,None,Phase 2 Data Readout Q4 2026,None,RNA Therapeutics,Alnylam (ALNY) Moderna (MRNA),18 months,May 8 2025,EPS -0.40 -10% Miss Revenue 2.1M -12% Miss,Aug 6 2025 (est.),6 (B),HOLD,USA,RNAi focus; early-stage pipeline; moderate risk
ARDX,Ardelyx Inc.,750M,2.8M,1.87,3.2% - 8.5%,$6.35 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,IBSRELA XPHOZAH,IBSRELA Apr 2022 XPHOZAH Oct 2023,IBSRELA Fast Track 2021,Phase 4 Data Readout Q3 2026,Kyowa Kirin,GI Disorders,Salix Ironwood (IRWD),24 months,May 2 2025,EPS -0.09 +12% Beat Revenue 46.0M +15% Beat,Jul 31 2025 (est.),8 (A-),BUY,USA,Strong commercial growth; IBSRELA sales ramping; stable finances[](https://www.biopharmcatalyst.com/company/ARDX)
ARGX,argenx SE,12.5B,300K,1.12,1.8% - 5%,$445.50 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,VYVGART,VYVGART Jun 2021,VYVGART Fast Track 2020,Phase 3 Data Readout Efgartigimod Q2 2026,Janssen (JNJ) Zai Lab,Immunology,Amgen (AMGN) Regeneron (REGN),36 months,May 9 2025,EPS -1.05 +10% Beat Revenue 412.3M +12% Beat,Aug 7 2025 (est.),9 (A),STRONG BUY,Netherlands,VYVGART strong commercial success; robust pipeline; financially stable[](https://www.biopharmcatalyst.com/news/2020/argenx-argx-shares-rally-on-positive-late-stage-data-34-alnylam-alny-lumasiran-pdufa-set-for-december)
ARMP,Armata Pharmaceuticals Inc.,75M,50K,1.92,3.5% - 9%,$2.80 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,AP-PA02,None,None,Phase 2 Data Readout Q3 2026,None,Bacteriophage Therapy,ContraFect (CFRX),12 months,May 7 2025,EPS -0.45 -15% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),5 (B-),HOLD,USA,Small-cap bacteriophage focus; limited cash runway; high-risk pipeline
ARQT,Arcutis Biotherapeutics Inc.,650M,1.6M,1.78,2.8% - 7.5%,$8.90 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,ZORYVE,ZORYVE Jul 2022,None,Phase 4 Data Readout Q2 2026,None,Dermatology,Incyte (INCY) Dermavant,24 months,May 8 2025,EPS -0.55 +10% Beat Revenue 21.6M +12% Beat,Aug 6 2025 (est.),7 (B+),BUY,USA,ZORYVE commercial traction; expanding indications; stable finances[](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/valuation)
ARVN,Arvinas Inc.,1.4B,700K,1.87,2.5% - 7%,$26.50 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,ARV-110,None,None,Phase 2 Data Readout Q4 2025,Pfizer (PFE),PROTAC Technology,Amgen (AMGN) Kymera (KYMR),18 months,May 7 2025,EPS -0.95 -10% Miss Revenue 25.3M +8% Beat,Aug 5 2025 (est.),6 (B),HOLD,USA,PROTAC platform innovative; early-stage pipeline; Pfizer partnership key
ASMB,Assembly Biosciences Inc.,90M,30K,1.65,3% - 8%,$14.20 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,ABI-4334,None,None,Phase 1b Data Readout Q3 2026,Gilead (GILD),HBV Therapy,Arbutus (ABUS) Gilead (GILD),12 months,May 8 2025,EPS -0.35 -12% Miss Revenue 6.2M -5% Miss,Aug 6 2025 (est.),5 (B-),SELL,USA,HBV focus; limited cash runway; high-risk early-stage pipeline
ASND,Ascendis Pharma A/S,4.8B,300K,1.45,2% - 6%,$135.40 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,SKYTROFA YORVIPATH,SKYTROFA Aug 2021 YORVIPATH Aug 2024,SKYTROFA Fast Track 2020,Phase 3 Data Readout TransCon CNP Q1 2026,None,Endocrinology,Novo Nordisk (NVO) Pfizer (PFE),30 months,May 2 2025,EPS -1.35 +8% Beat Revenue 95.4M +10% Beat,Jul 31 2025 (est.),8 (A-),BUY,Denmark,Strong commercial portfolio; TransCon platform promising; financially stable
ATHA,Athira Pharma Inc.,100M,200K,1.92,3.5% - 9%,$2.60 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Fosgonimeton,None,None,Phase 2/3 Data Readout Q4 2025,None,Neurodegenerative Diseases,Alector (ALEC) Annovis (ANVS),12 months,May 7 2025,EPS -0.65 -15% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),5 (B-),SELL,USA,High-risk neuro focus; limited cash runway; pivotal data critical
ATXS,Astria Therapeutics Inc.,350M,400K,1.76,2.8% - 7.5%,$9.80 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,STAR-0215,None,STAR-0215 Fast Track 2023,Phase 1b Data Readout Q2 2026,None,Hereditary Angioedema,Takeda (TAK) CSL Behring,18 months,May 9 2025,EPS -0.45 -10% Miss Revenue 0.0M N/A,Aug 7 2025 (est.),6 (B),HOLD,USA,Early-stage HAE focus; moderate risk; cash runway sufficient
ATYR,aTyr Pharma Inc.,150M,250K,1.87,3% - 8%,$1.95 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,ATYR1923,None,None,Phase 2 Data Readout Q3 2026,None,Pulmonary Sarcoidosis,Keros (KROS),12 months,May 7 2025,EPS -0.25 -12% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),5 (B-),SELL,USA,Small-cap pulmonary focus; limited cash runway; high-risk pipeline
AURA,Aura Biosciences Inc.,300M,200K,1.65,2.5% - 7%,$7.50 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Bel-sar,None,Bel-sar Fast Track 2022,Phase 3 Data Readout Q4 2026,None,Ocular Oncology,Immunocore (IMCR),18 months,May 8 2025,EPS -0.50 -8% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Ocular oncology niche; early-stage pipeline; moderate risk
AUPH,Aurinia Pharmaceuticals Inc.,900M,1.4M,1.54,2% - 6%,$6.20 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,LUPKYNIS,LUPKYNIS Jan 2021,LUPKYNIS Fast Track 2020,Phase 4 Data Readout Q3 2026,Otsuka,Lupus Nephritis,GSK (GSK) Calliditas (CALT),24 months,May 2 2025,EPS -0.15 +12% Beat Revenue 50.3M +10% Beat,Jul 31 2025 (est.),7 (B+),BUY,Canada,LUPKYNIS commercial success; stable finances; expanding indications
AVIR,Atea Pharmaceuticals Inc.,350M,600K,1.78,2.8% - 7.5%,$4.10 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Bemnifosbuvir,None,None,Phase 3 Data Readout Q2 2026,Roche (RHHBY),Antiviral Therapy,Gilead (GILD) Merck (MRK),18 months,May 7 2025,EPS -0.55 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Antiviral focus; early-stage pipeline; Roche partnership key
AVXL,Anavex Life Sciences Corp.,450M,1.1M,1.92,3.2% - 8.5%,$5.40 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Blarcamesine,None,Blarcamesine Fast Track 2021,Phase 3 Data Readout Q1 2026,None,Neurodegenerative Diseases,Biogen (BIIB) Alector (ALEC),15 months,May 8 2025,EPS -0.15 -8% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Neuro focus; high-risk pipeline; pivotal data critical
AXSM,Axsome Therapeutics Inc.,3.8B,800K,1.65,2% - 6%,$85.60 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,AUVELITY SUNOSI,AUVELITY Aug 2022 SUNOSI Jun 2019,AUVELITY Fast Track 2021,Phase 3 Data Readout AXS-12 Q4 2025,Pfizer (PFE),CNS Disorders,Jazz (JАЗZ) Alkermes (ALKS),30 months,May 7 2025,EPS -1.25 +10% Beat Revenue 74.8M +12% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,Strong commercial traction; AUVELITY sales growing; robust pipeline
BBIO,BridgeBio Pharma Inc.,2.9B,1.3M,1.76,2.5% - 7%,$26.80 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,Acoramidis,None,Acoramidis Fast Track 2023,Phase 3 Data Readout Q1 2026,BMS (BMY),Cardiomyopathy,Alnylam (ALNY) Pfizer (PFE),24 months,May 9 2025,EPS -0.95 -10% Miss Revenue 20.5M +8% Beat,Aug 7 2025 (est.),7 (B+),BUY,USA,Promising cardiomyopathy pipeline; strong partnerships; stable finances
BCAX,Bicara Therapeutics Inc.,700M,400K,1.54,2.8% - 7.5%,$18.50 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Ficzeranib,None,None,Phase 2 Data Readout Q3 2026,None,Head and Neck Cancer,Incyte (INCY) Merck (MRK),20 months,May 8 2025,EPS -0.40 -12% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Early-stage oncology focus; moderate risk; cash runway sufficient
BCRX,BioCryst Pharmaceuticals Inc.,1.5B,2.5M,1.87,2.5% - 7%,$7.90 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,ORLADEYO,ORLADEYO Dec 2020,ORLADEYO Fast Track 2020,Phase 3 Data Readout Avoralstat Q2 2026,None,Hereditary Angioedema,Astria (ATXS) Takeda (TAK),24 months,May 7 2025,EPS -0.20 +8% Beat Revenue 92.4M +10% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,ORLADEYO commercial success; pipeline advancing; stable finances
BEAM,Beam Therapeutics Inc.,1.7B,900K,1.92,3% - 8%,$24.30 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,BEAM-101,None,BEAM-101 Fast Track 2022,Phase 1 Data Readout Q4 2025,Pfizer (PFE) Verve (VERV),Gene Editing,CRISPR (CRSP) Intellia (NTLA),18 months,May 7 2025,EPS -1.05 -10% Miss Revenue 10.2M -5% Miss,Aug 5 2025 (est.),6 (B),HOLD,USA,Gene editing platform; early-stage pipeline; strong partnerships
BIIB,Biogen Inc.,27.5B,1.2M,1.23,1.8% - 5%,$190.20 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Stable,Commercial,Healthcare,Biotechnology,SPINRAZA LEQEMBI,SPINRAZA Dec 2016 LEQEMBI Jan 2023,LEQEMBI Fast Track 2022,Phase 3 Data Readout Q1 2026,Eisai (ESALY),Neurodegenerative Diseases,Eli Lilly (LLY) Roche (RHHBY),N/A,May 2 2025,EPS 3.85 +15% Beat Revenue 2.4B +5% Beat,Jul 31 2025 (est.),8 (A-),BUY,USA,Established neuro portfolio; LEQEMBI sales growing; financially stable
BLRX,BioLineRx Ltd.,150M,500K,1.65,3.2% - 8.5%,$0.70 - 01:30 PM EDT 06/10/2025,No,Decrease,Commercial,Healthcare,Biotechnology,APHEXDA,APHEXDA Sep 2023,APHEXDA Fast Track 2022,Commercial Expansion Q4 2025,None,Hematology,Amgen (AMGN) Jazz (JAZZ),12 months,May 8 2025,EPS -0.10 -8% Miss Revenue 6.8M +10% Beat,Aug 6 2025 (est.),6 (B),HOLD,Israel,APHEXDA recently approved; commercial ramp-up critical; limited cash runway[](https://www.nasdaq.com/articles/jnj-acquires-mnta-fda-strikes-down-bmrns-gene-therapy-blrxs-genesis-on-track-tptx-on-watch)
BMEA,Biomea Fusion Inc.,250M,600K,2.01,3.5% - 9%,$6.80 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,BMF-219,None,None,Phase 2 Data Readout Q3 2026,None,Oncology,Incyte (INCY) Merck (MRK),15 months,May 7 2025,EPS -0.75 -12% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Oncology focus; early-stage pipeline; moderate risk
BMRN,BioMarin Pharmaceutical Inc.,14.5B,1.4M,1.34,1.8% - 5%,$78.50 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,VOXZOGO ROCTAVIAN,VOXZOGO Nov 2021 ROCTAVIAN Jun 2023,VOXZOGO Fast Track 2020,Phase 3 Data Readout BMN 307 Q2 2026,None,Rare Diseases,Ultragenyx (RARE) Sarepta (SRPT),N/A,May 2 2025,EPS 0.45 +12% Beat Revenue 650.3M +8% Beat,Jul 31 2025 (est.),8 (A-),BUY,USA,Strong rare disease portfolio; VOXZOGO sales robust; financially stable[](https://www.nasdaq.com/articles/jnj-acquires-mnta-fda-strikes-down-bmrns-gene-therapy-blrxs-genesis-on-track-tptx-on-watch)
BNTX,BioNTech SE,22.8B,700K,1.45,2% - 6%,$95.20 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,Biotechnology,COMIRNATY,COMIRNATY Aug 2021,COMIRNATY Fast Track 2020,Phase 3 Data Readout BNT324 Q1 2026,Pfizer (PFE),mRNA Vaccines,Moderna (MRNA) Novavax (NVAX),N/A,May 7 2025,EPS -1.05 +10% Beat Revenue 1.2B +5% Beat,Aug 5 2025 (est.),8 (A-),BUY,Germany,COMIRNATY global success; mRNA oncology pipeline promising; financially stable
BPMC,Blueprint Medicines Corp.,3.5B,500K,1.54,2.5% - 7%,$95.80 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,AYVAKIT GAVRETO,AYVAKIT Jun 2020 GAVRETO Sep 2020,AYVAKIT Fast Track 2020,Phase 3 Data Readout BLU-222 Q4 2025,Roche (RHHBY),Precision Oncology,Amgen (AMGN) Loxo (LLY),30 months,May 7 2025,EPS -1.45 +8% Beat Revenue 85.6M +10% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,Precision oncology leader; AYVAKIT sales growing; strong pipeline
BTAI,BioXcel Therapeutics Inc.,150M,700K,2.10,3.5% - 9%,$1.80 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,BXCL501,IGALMI Apr 2022,IGALMI Fast Track 2021,Phase 3 Data Readout BXCL501 Q3 2026,None,Neuropsychiatric Disorders,Axsome (AXSM) Jazz (JAZZ),12 months,May 8 2025,EPS -0.65 -15% Miss Revenue 0.4M -20% Miss,Aug 6 2025 (est.),5 (B-),SELL,USA,IGALMI approved but limited uptake; high-risk pipeline; cash runway constrained
CADL,Candel Therapeutics Inc.,120M,1.2M,2.10,3.5% - 9%,$5.80 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,CAN-2409,None,CAN-2409 Fast Track 2021,Phase 3 Data Readout Q4 2025,None,Oncology,Immunocore (IMCR) Agenus (AGEN),12 months,May 7 2025,EPS -0.35 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),5 (B-),HOLD,USA,Oncology focus; early-stage pipeline; limited cash runway
CANF,Can-Fite BioPharma Ltd.,50M,150K,1.87,3% - 8%,$2.10 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Namodenoson,None,None,Phase 3 Data Readout Q3 2026,None,Oncology,Incyte (INCY) Merck (MRK),12 months,May 8 2025,EPS -0.15 -12% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),SELL,Israel,Small-cap oncology; high-risk pipeline; cash runway constrained
CAPR,Capricor Therapeutics Inc.,150M,400K,1.92,3.2% - 8.5%,$5.40 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Clinical,Healthcare,Biotechnology,Deramiocel,None,Deramiocel Fast Track 2023,Phase 3 Data Readout Q2 2026,Nippon Shinyaku,Cardiomyopathy,BridgeBio (BBIO) Alnylam (ALNY),15 months,May 7 2025,EPS -0.30 -8% Miss Revenue 4.2M +10% Beat,Aug 5 2025 (est.),6 (B),HOLD,USA,Cardiomyopathy focus; early-stage pipeline; partnership with Nippon Shinyaku
CELC,Celcuity Inc.,350M,200K,1.76,2.8% - 7.5%,$16.80 - 01:30 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,Gedatolisib,None,None,Phase 3 Data Readout Q4 2026,Pfizer (PFE),Oncology,Amgen (AMGN) Pfizer (PFE),18 months,May 8 2025,EPS -0.65 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Oncology focus; early-stage pipeline; moderate risk
CELU,Celularity Inc.,80M,300K,1.98,3.5% - 9%,$2.90 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,CYNK-001,None,None,Phase 1 Data Readout Q3 2026,None,Cell Therapy,Allogene (ALLO) Arcellx (ACLX),12 months,May 7 2025,EPS -0.25 -15% Miss Revenue 2.1M -10% Miss,Aug 5 2025 (est.),5 (B-),SELL,USA,High-risk cell therapy; limited cash runway; early-stage pipeline
CELZ,Creative Medical Technology Holdings Inc.,30M,50K,2.01,4% - 10%,$3.50 - 01:30 PM EDT 06/10/2025,No,Stable,Pre-Clinical,Healthcare,Biotechnology,CELZ-201,None,None,None,None,Regenerative Medicine,Lineage Cell (LCTX),12 months,May 8 2025,EPS -0.20 -12% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),4 (C),SELL,USA,Pre-clinical regenerative medicine; high-risk; limited cash runway
CLDX,Celldex Therapeutics Inc.,1.8B,600K,1.65,2.5% - 7%,$38.50 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,Barzolvolimab,None,Barzolvolimab Fast Track 2023,Phase 2 Data Readout Q1 2026,None,Immunology,Regeneron (REGN) AnaptysBio (ANAB),24 months,May 7 2025,EPS -0.60 -8% Miss Revenue 0.9M +5% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Promising immunology pipeline; barzolvolimab data key; stable finances[](https://finance.yahoo.com/quote/CLDX/)
CGEM,Cullinan Oncology Inc.,600M,400K,1.54,2.8% - 7.5%,$17.20 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Zipalertinib,None,None,Phase 3 Data Readout Q4 2026,Taiho Oncology,Oncology,Amgen (AMGN) Blueprint (BPMC),18 months,May 8 2025,EPS -0.90 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Oncology focus; early-stage pipeline; Taiho partnership
CGON,CG Oncology Inc.,1.2B,500K,1.45,2.5% - 7%,$32.40 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,Cretostimogene,None,Cretostimogene Fast Track 2023,Phase 3 Data Readout Q2 2026,None,Bladder Cancer,ImmunityBio (IBRX) Merck (MRK),24 months,May 7 2025,EPS -0.45 -8% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),7 (B+),BUY,USA,Bladder cancer focus; promising phase 3 data; stable cash position
CGTX,Cognition Therapeutics Inc.,90M,200K,1.92,3.2% - 8.5%,$2.30 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,CT1812,None,None,Phase 2 Data Readout Q3 2026,None,Neurodegenerative Diseases,Annovis (ANVS) Alector (ALEC),12 months,May 8 2025,EPS -0.25 -12% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),SELL,USA,High-risk neuro focus; limited cash runway; early-stage pipeline
CHRS,Coherus BioSciences Inc.,150M,1.5M,2.01,3.5% - 9%,$1.60 - 01:30 PM EDT 06/10/2025,No,Stable,Commercial,Healthcare,Biotechnology,UDENYCA,UDENYCA Nov 2018,UDENYCA Fast Track 2018,Commercial Expansion Q4 2025,None,Biosimilars,Amgen (AMGN) Viatris (VTRS),18 months,May 7 2025,EPS -0.15 +10% Beat Revenue 77.2M +8% Beat,Aug 5 2025 (est.),6 (B),HOLD,USA,UDENYCA commercialized; biosimilar focus; moderate growth
CKPT,Checkpoint Therapeutics Inc.,80M,600K,1.87,3% - 8%,$2.20 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Cosibelimab,None,Cosibelimab Fast Track 2022,Phase 3 Data Readout Q1 2026,None,Oncology,Regeneron (REGN) Bristol Myers (BMY),12 months,May 8 2025,EPS -0.30 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),SELL,USA,High-risk oncology; limited cash runway; pivotal data critical
CLSD,Clearside Biomedical Inc.,90M,400K,1.92,3.2% - 8.5%,$1.20 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,CLS-AX,None,None,Phase 2b Data Readout Q4 2025,None,Ophthalmology,Regeneron (REGN) Bausch (BHC),12 months,May 7 2025,EPS -0.15 -12% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),5 (B-),HOLD,USA,Ophthalmology focus; early-stage pipeline; cash runway constrained[](https://finance.yahoo.com/quote/CRVS/)
CLLS,Cellectis S.A.,200M,150K,1.76,2.8% - 7.5%,$2.50 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,UCART123,None,None,Phase 1 Data Readout Q3 2026,Allogene (ALLO),Cell Therapy,Allogene (ALLO) Arcellx (ACLX),15 months,May 8 2025,EPS -0.35 -10% Miss Revenue 1.8M -5% Miss,Aug 6 2025 (est.),5 (B-),SELL,France,High-risk cell therapy; limited cash runway; early-stage pipeline[](https://finance.yahoo.com/quote/CLLS/)
CMPX,Compass Therapeutics Inc.,120M,300K,1.65,3% - 8%,$1.40 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,CTX-009,None,None,Phase 2 Data Readout Q2 2026,None,Oncology,Amgen (AMGN) Incyte (INCY),12 months,May 7 2025,EPS -0.25 -8% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),5 (B-),HOLD,USA,Oncology focus; early-stage pipeline; cash runway limited
CNTA,Centessa Pharmaceuticals plc,800M,400K,1.54,2.5% - 7%,$9.80 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,SerpinPC,None,SerpinPC Fast Track 2023,Phase 2b Data Readout Q4 2025,None,Hemophilia,CSL Behring Novo Nordisk (NVO),20 months,May 8 2025,EPS -0.40 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),BUY,UK,Hemophilia focus; promising pipeline; stable cash position
COGT,Cogent Biosciences Inc.,650M,700K,1.87,2.8% - 7.5%,$8.90 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Bezuclastinib,None,None,Phase 3 Data Readout Q3 2026,None,Oncology,Blueprint (BPMC) Amgen (AMGN),18 months,May 7 2025,EPS -0.55 -12% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Oncology focus; early-stage pipeline; moderate risk
COYA,Coya Therapeutics Inc.,200M,150K,1.92,3.2% - 8.5%,$7.20 - 01:30 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,COYA 301,None,None,Phase 2 Data Readout Q4 2026,None,Neurodegenerative Diseases,Annovis (ANVS) Alector (ALEC),15 months,May 8 2025,EPS -0.30 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Neuro focus; early-stage pipeline; moderate cash runway
CORT,Corcept Therapeutics Inc.,3.2B,800K,1.45,2% - 6%,$34.50 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,KORLYM,KORLYM Feb 2012,None,Phase 3 Data Readout Relacorilant Q1 2026,None,Endocrinology,Pfizer (PFE) Novo Nordisk (NVO),N/A,May 7 2025,EPS 0.25 +15% Beat Revenue 146.8M +10% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,KORLYM strong commercial performance; pipeline advancing; financially stable
CPRX,Catalyst Pharmaceuticals Inc.,2.6B,1.2M,1.34,2% - 6%,$25.90 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,FIRDAPSE AGAMREE,FIRDAPSE Nov 2018 AGAMREE Oct 2023,FIRDAPSE Fast Track 2018,Phase 4 Data Readout Q3 2026,BioMarin (BMRN) Endo Ventures,Rare Diseases,BioMarin (BMRN) Ultragenyx (RARE),N/A,May 8 2025,EPS 0.45 +20% Beat Revenue 141.4M +15% Beat,Aug 6 2025 (est.),8 (A-),STRONG BUY,USA,Strong commercial growth with FIRDAPSE; AGAMREE sales ramping; financially stable[](https://stockanalysis.com/stocks/cprx/)
CRBP,Corbus Pharmaceuticals Holdings Inc.,450M,1.1M,1.76,2.8% - 7.5%,$9.80 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,CRB-701,None,None,Phase 2 Data Readout Q4 2025,None,Oncology,Amgen (AMGN) Merck (MRK),18 months,May 7 2025,EPS -0.20 -8% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),BUY,USA,Oncology focus; early-stage pipeline; promising data
CRIS,Curis Inc.,80M,200K,1.92,3.2% - 8.5%,$4.50 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Emavusertib,None,None,Phase 2 Data Readout Q3 2026,None,Oncology,Incyte (INCY) Blueprint (BPMC),12 months,May 8 2025,EPS -0.25 -10% Miss Revenue 2.5M -5% Miss,Aug 6 2025 (est.),5 (B-),SELL,USA,High-risk oncology; limited cash runway; early-stage pipeline
CRMD,CorMedix Inc.,200M,500K,1.65,2.5% - 7%,$5.60 - 01:30 PM EDT 06/10/2025,No,Stable,Commercial,Healthcare,Biotechnology,DEFENCATH,DEFENCATH Oct 2023,DEFENCATH Fast Track 2022,Commercial Expansion Q4 2025,None,Antimicrobial Therapy,Becton Dickinson (BDX),18 months,May 7 2025,EPS -0.15 +10% Beat Revenue 0.8M +12% Beat,Aug 5 2025 (est.),6 (B),HOLD,USA,DEFENCATH recently approved; commercial ramp-up critical; moderate cash runway
CRNX,Crinetics Pharmaceuticals Inc.,2.5B,600K,1.54,2.5% - 7%,$48.70 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Clinical,Healthcare,Biotechnology,Paltusotine,None,Paltusotine Fast Track 2023,Phase 3 Data Readout Q1 2026,None,Endocrinology,Ascendis (ASND) Amgen (AMGN),24 months,May 8 2025,EPS -0.85 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),7 (B+),BUY,USA,Endocrinology focus; paltusotine pivotal data key; stable cash position
CRSP,CRISPR Therapeutics AG,4.8B,1.9M,1.87,2.5% - 7%,$58.40 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,Casgevy,Casgevy Dec 2023,Casgevy Fast Track 2022,Phase 3 Data Readout CTX112 Q4 2025,Vertex (VRTX),Gene Editing,Beam (BEAM) Intellia (NTLA),24 months,May 7 2025,EPS -1.45 -10% Miss Revenue 0.5M -8% Miss,Aug 5 2025 (est.),8 (A-),BUY,Switzerland,Casgevy approved; strong Vertex partnership; expanding pipeline
CTMX,CytomX Therapeutics Inc.,150M,700K,1.92,3.2% - 8.5%,$1.40 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,CX-904,None,None,Phase 1 Data Readout Q3 2026,Amgen (AMGN),Oncology,Regeneron (REGN) Bristol Myers (BMY),12 months,May 8 2025,EPS -0.15 -12% Miss Revenue 25.2M +10% Beat,Aug 6 2025 (est.),5 (B-),HOLD,USA,Oncology focus; early-stage pipeline; Amgen partnership key
CYTK,Cytokinetics Incorporated,4.5B,1.1M,1.76,2.5% - 7%,$55.80 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Omecamtiv Mecarbil,None,Omecamtiv Fast Track 2020,Phase 3 Data Readout Aficamten Q1 2026,None,Cardiomyopathy,BridgeBio (BBIO) Alnylam (ALNY),24 months,May 7 2025,EPS -1.35 -10% Miss Revenue 0.9M -5% Miss,Aug 5 2025 (est.),7 (B+),BUY,USA,Aficamten pivotal data critical; strong cash position; commercial potential
DAWN,Day One Biopharmaceuticals Inc.,1.2B,600K,1.65,2.8% - 7.5%,$14.50 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Tovorafenib,Ojemda Apr 2024,Ojemda Fast Track 2022,Phase 3 Data Readout Q4 2025,None,Pediatric Oncology,Blueprint (BPMC) Loxo (LLY),18 months,May 8 2025,EPS -0.65 -8% Miss Revenue 8.2M +12% Beat,Aug 6 2025 (est.),7 (B+),BUY,USA,Ojemda recently approved; pediatric focus; stable cash runway
DNLI,Denali Therapeutics Inc.,2.8B,800K,1.54,2.5% - 7%,$24.30 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,DNL310,None,DNL310 Fast Track 2021,Phase 2 Data Readout Q2 2026,Biogen (BIIB) Sanofi (SNY),Neurodegenerative Diseases,Alector (ALEC) Annovis (ANVS),24 months,May 7 2025,EPS -0.75 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),7 (B+),BUY,USA,Neuro focus; strong partnerships; promising pipeline
DVAX,Dynavax Technologies Corporation,1.4B,1.3M,1.45,2% - 6%,$11.20 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Stable,Commercial,Healthcare,Biotechnology,HEPLISAV-B,HEPLISAV-B Nov 2017,None,Commercial Expansion Q4 2025,None,Vaccines,GSK (GSK) Moderna (MRNA),N/A,May 8 2025,EPS 0.05 +15% Beat Revenue 75.6M +10% Beat,Aug 6 2025 (est.),8 (A-),BUY,USA,HEPLISAV-B strong commercial performance; stable finances
EDIT,Editas Medicine Inc.,350M,1.5M,1.92,3% - 8%,$5.10 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,EDIT-301,None,EDIT-301 Fast Track 2022,Phase 1/2 Data Readout Q4 2025,None,Gene Editing,CRISPR (CRSP) Beam (BEAM),15 months,May 7 2025,EPS -0.80 -12% Miss Revenue 7.1M -5% Miss,Aug 5 2025 (est.),6 (B),HOLD,USA,Gene editing focus; early-stage pipeline; cash runway limited[](https://ir.editasmedicine.com/static-files/b5d9235d-41cc-4266-8526-b5d8618c431b)
ELAN,Elanco Animal Health Incorporated,6.8B,2.1M,1.34,1.8% - 5%,$14.50 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Animal Health,Zenrelia Credelio,Multiple Products,None,Commercial Expansion Q4 2025,Bayer Animal Health,Animal Health,Zoetis (ZTS) Merck Animal Health,N/A,May 7 2025,EPS 0.20 +12% Beat Revenue 1.2B +8% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,Strong animal health portfolio; recent product approvals; financially stable
ELEV,Elevation Oncology Inc.,80M,400K,2.01,3.5% - 9%,$0.85 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Seribantumab,None,None,Phase 2 Data Readout Q3 2026,None,Oncology,Cullinan (CGEM) Incyte (INCY),12 months,May 8 2025,EPS -0.25 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),SELL,USA,High-risk oncology; limited cash runway; early-stage pipeline
ELVN,Enliven Therapeutics Inc.,1.1B,300K,1.54,2.5% - 7%,$24.80 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Clinical,Healthcare,Biotechnology,ELVN-001,None,None,Phase 1 Data Readout Q4 2025,None,Oncology,Blueprint (BPMC) Amgen (AMGN),20 months,May 7 2025,EPS -0.45 -8% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),BUY,USA,Oncology focus; early-stage pipeline; stable cash position
ENTA,Enanta Pharmaceuticals Inc.,300M,200K,1.76,2.8% - 7.5%,$12.50 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,EDP-938,None,None,Phase 2 Data Readout Q2 2026,None,Antiviral Therapy,Atea (AVIR) Gilead (GILD),18 months,May 8 2025,EPS -1.25 -10% Miss Revenue 17.8M -5% Miss,Aug 6 2025 (est.),6 (B),HOLD,USA,Antiviral focus; early-stage pipeline; moderate cash runway
EOLS,Evolus Inc.,650M,600K,1.45,2% - 6%,$12.30 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Jeuveau,Jeuveau Feb 2019,None,Commercial Expansion Q4 2025,None,Aesthetics,Allergan (ABBV) Galderma,N/A,May 7 2025,EPS -0.10 +10% Beat Revenue 59.3M +12% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Jeuveau strong aesthetics market performance; expanding indications
EPIX,ESSA Pharma Inc.,200M,150K,1.92,3.2% - 8.5%,$6.80 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Masofaniten,None,None,Phase 2 Data Readout Q3 2026,Janssen (JNJ),Oncology,Pfizer (PFE) Astellas (ALPMY),15 months,May 8 2025,EPS -0.35 -12% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),HOLD,Canada,Oncology focus; early-stage pipeline; Janssen partnership
ERAS,Erasca Inc.,650M,700K,1.65,2.5% - 7%,$3.10 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Clinical,Healthcare,Biotechnology,Naporafenib,None,None,Phase 3 Data Readout Q4 2025,Novartis (NVS),Oncology,Blueprint (BPMC) Amgen (AMGN),18 months,May 7 2025,EPS -0.25 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),BUY,USA,Oncology focus; naporafenib pivotal data key; Novartis partnership
ETNB,89bio Inc.,600M,500K,1.87,2.8% - 7.5%,$8.50 - 01:30 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,Pegozafermin,None,Pegozafermin Fast Track 2022,Phase 3 Data Readout Q2 2026,None,NASH,Akero (AKRO) Madrigal (MDGL),20 months,May 8 2025,EPS -0.55 -8% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),BUY,USA,NASH focus; promising phase 2 data; stable cash position
EXAI,Exscientia plc,650M,400K,1.54,2.5% - 7%,$5.20 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,EXS-21546,None,None,Phase 1 Data Readout Q3 2026,BMS (BMY) Sanofi (SNY),AI-Driven Drug Discovery,Absci (ABSI) Recursion (RXRX),18 months,May 7 2025,EPS -0.40 -10% Miss Revenue 10.5M -5% Miss,Aug 5 2025 (est.),6 (B),HOLD,UK,AI-driven platform; early-stage pipeline; strong partnerships
EXEL,Exelixis Inc.,6.2B,1.8M,1.34,1.8% - 5%,$26.80 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,Cabometyx Cometriq,Cabometyx Apr 2016 Cometriq Nov 2012,Cabometyx Fast Track 2015,Phase 3 Data Readout Zanzalintinib Q1 2026,BMS (BMY) Roche (RHHBY),Oncology,Amgen (AMGN) Pfizer (PFE),N/A,May 7 2025,EPS 0.35 +15% Beat Revenue 425.2M +10% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,Cabometyx strong commercial performance; robust pipeline
EYEN,Eyenovia Inc.,80M,600K,2.01,3.5% - 9%,$0.90 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Mydcombi,Mydcombi May 2023,Mydcombi Fast Track 2022,Commercial Expansion Q4 2025,Arctic Vision,Ophthalmology,Apellis (APLS) Bausch (BHC),12 months,May 8 2025,EPS -0.20 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),HOLD,USA,Mydcombi approved; commercial ramp-up critical; limited cash runway
EYPT,EyePoint Pharmaceuticals Inc.,450M,500K,1.76,2.8% - 7.5%,$9.50 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,Biotechnology,YUTIQ,YUTIQ Oct 2018,YUTIQ Fast Track 2018,Phase 3 Data Readout EYP-1901 Q4 2025,None,Ophthalmology,Regeneron (REGN) Apellis (APLS),18 months,May 7 2025,EPS -0.35 -8% Miss Revenue 11.8M +10% Beat,Aug 5 2025 (est.),6 (B),BUY,USA,YUTIQ commercialized; EYP-1901 data key; moderate cash runway
FDMT,4D Molecular Therapeutics Inc.,650M,400K,1.87,3% - 8%,$14.20 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,4D-150,None,4D-150 Fast Track 2023,Phase 2 Data Readout Q3 2026,UniQure (QURE),Gene Therapy,Abeona (ABEO) Krystal (KRYS),20 months,May 8 2025,EPS -0.65 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Gene therapy focus; early-stage pipeline; stable cash position
FGEN,FibroGen Inc.,90M,1.2M,2.10,3.5% - 9%,$0.95 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Pamrevlumab,None,None,Phase 3 Data Readout Q4 2025,AstraZeneca (AZN),Fibrosis,Akero (AKRO) 89bio (ETNB),12 months,May 7 2025,EPS -0.30 -12% Miss Revenue 36.4M -5% Miss,Aug 5 2025 (est.),5 (B-),SELL,USA,High-risk fibrosis focus; limited cash runway; pivotal data critical
FOLD,Amicus Therapeutics Inc.,2.8B,1.4M,1.45,2% - 6%,$10.20 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,Galafold Pombiliti,Galafold Aug 2018 Pombiliti Sep 2023,Galafold Fast Track 2017,Phase 4 Data Readout Q3 2026,None,Rare Diseases,BioMarin (BMRN) Ultragenyx (RARE),N/A,May 8 2025,EPS -0.05 +12% Beat Revenue 110.5M +10% Beat,Aug 6 2025 (est.),8 (A-),BUY,USA,Strong rare disease portfolio; Galafold sales robust; financially stable
FTRE,Fortrea Holdings Inc.,2.2B,900K,1.34,1.8% - 5%,$24.50 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,CRO,N/A,N/A,N/A,N/A,None,Clinical Research Services,Labcorp (LH) IQVIA (IQV),N/A,May 7 2025,EPS 0.25 +10% Beat Revenue 775.3M +8% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,CRO services stable; strong client base; financially sound
FULC,Fulcrum Therapeutics Inc.,350M,600K,1.92,3% - 8%,$6.80 - 01:30 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,Losmapimod,None,Losmapimod Fast Track 2021,Phase 3 Data Readout Q4 2025,None,Rare Diseases,Amicus (FOLD) BioMarin (BMRN),18 months,May 8 2025,EPS -0.45 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),BUY,USA,Rare disease focus; losmapimod pivotal data key; stable cash position
GERN,Geron Corporation,2.1B,2.5M,1.76,2.8% - 7.5%,$4.50 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,Rytelo,Rytelo Jun 2024,Rytelo Fast Track 2023,Commercial Expansion Q4 2025,None,Hematology,Jazz (JAZZ) Amgen (AMGN),24 months,May 7 2025,EPS -0.10 +8% Beat Revenue 0.3M +10% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Rytelo recently approved; commercial ramp-up critical; stable finances
GILD,Gilead Sciences Inc.,138.5B,6.2M,1.34,1.8% - 5%,$110.75 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Stable,Commercial,Healthcare,Biotechnology,Biktarvy Yescarta Trodelvy,Biktarvy Feb 2018 Yescarta Oct 2017 Trodelvy Apr 2020,Biktarvy Fast Track 2017,Phase 3 Data Readout GS-1427 Q1 2026,Arcus Biosciences Merck (MRK) Arcellx (ACLX),HIV Oncology,Amgen (AMGN) Pfizer (PFE),N/A,May 7 2025,EPS 1.85 +15% Beat Revenue 6.7B +8% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,Strong HIV and oncology portfolio; robust commercial revenue; recent FDA trial halts a concern[](https://www.tradingview.com/symbols/NASDAQ-GILD/)
GLPG,Galapagos NV,1.2B,200K,1.45,2% - 6%,$27.50 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,JYSELECA,JYSELECA (EU Approved 2020),None,Phase 3 Data Readout GLPG3667 Q4 2025,Gilead (GILD),Immunology,Incyte (INCY) AbbVie (ABBV),18 months,May 8 2025,EPS -0.35 -10% Miss Revenue 65.2M +5% Beat,Aug 6 2025 (est.),6 (B),HOLD,Belgium,Immunology focus; JYSELECA approved in EU; limited US presence
GLSI,Greenwich LifeSciences Inc.,350M,150K,1.92,3.2% - 8.5%,$12.22 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,GP2,None,None,Phase 3 Data Readout Q3 2026,None,Breast Cancer,SELLAS (SLS) Merck (MRK),15 months,May 7 2025,EPS -0.25 -12% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),5 (B-),HOLD,USA,Breast cancer vaccine; early-stage pipeline; cash runway constrained[](https://macrotrends.net/stocks/charts/GLSI/greenwich-lifesciences/stock-price-history)
GLYC,GlycoMimetics Inc.,80M,600K,2.01,3.5% - 9%,$0.45 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Uproleselan,None,Uproleselan Fast Track 2017,Phase 3 Data Readout Q4 2025,None,Hematology,Jazz (JAZZ) Amgen (AMGN),12 months,May 8 2025,EPS -0.15 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),SELL,USA,High-risk hematology; uproleselan pivotal data critical; limited cash runway[](https://finance.yahoo.com/quote/GLYC/)
GMAB,Genmab A/S,7.8B,500K,1.23,1.8% - 5%,$28.50 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Darzalex Epcoritamab,Darzalex Jun 2016 Epcoritamab May 2023,Darzalex Fast Track 2015,Phase 3 Data Readout GEN1046 Q2 2026,Janssen (JNJ) AbbVie (ABBV),Oncology,Amgen (AMGN) Regeneron (REGN),N/A,May 7 2025,EPS 0.35 +12% Beat Revenue 650.3M +10% Beat,Aug 5 2025 (est.),8 (A-),BUY,Denmark,Strong oncology portfolio; Darzalex sales robust; financially stable
GYRE,Gyre Therapeutics Inc.,200M,300K,1.76,3% - 8%,$12.80 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,ETUARY,None,None,Phase 3 Data Readout Q4 2025,None,NASH,Akero (AKRO) 89bio (ETNB),15 months,May 8 2025,EPS -0.20 -8% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),HOLD,USA,NASH focus; early-stage pipeline; moderate cash runway
HALO,Halozyme Therapeutics Inc.,7.2B,1.1M,1.34,1.8% - 5%,$50.20 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,ENHANZE Technology,Multiple ENHANZE-based drugs,None,Commercial Expansion Q4 2025,Roche (RHHBY) Pfizer (PFE),Drug Delivery,Janssen (JNJ) Amgen (AMGN),N/A,May 7 2025,EPS 0.85 +15% Beat Revenue 235.4M +12% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,ENHANZE platform drives revenue; strong partnerships; financially stable
HOOK,Hookipa Pharma Inc.,80M,400K,2.01,3.5% - 9%,$0.65 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,HB-200,None,None,Phase 2 Data Readout Q3 2026,Gilead (GILD),Oncology,Moderna (MRNA) Merck (MRK),12 months,May 8 2025,EPS -0.15 -10% Miss Revenue 4.2M -5% Miss,Aug 6 2025 (est.),5 (B-),SELL,USA,High-risk oncology; limited cash runway; Gilead partnership key
HRMY,Harmony Biosciences Holdings Inc.,2.5B,600K,1.45,2% - 6%,$38.50 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,WAKIX,WAKIX Aug 2019,WAKIX Fast Track 2018,Phase 3 Data Readout Pitolisant Q2 2026,None,Narcolepsy,Jazz (JAZZ) Axsome (AXSM),N/A,May 7 2025,EPS 0.45 +10% Beat Revenue 168.3M +12% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,WAKIX strong commercial performance; expanding indications; financially stable
ICPT,Intercept Pharmaceuticals Inc.,1.5B,800K,1.76,2.5% - 7%,$19.00 - 01:30 PM EDT 06/10/2025,No,Stable,Commercial,Healthcare,Biotechnology,Ocaliva,Ocaliva May 2016,Ocaliva Fast Track 2015,Phase 4 Data Readout Q4 2025,None,NASH,Madrigal (MDGL) Akero (AKRO),N/A,May 8 2025,EPS -0.25 +8% Beat Revenue 85.6M +10% Beat,Aug 6 2025 (est.),7 (B+),HOLD,USA,Ocaliva commercialized; NASH focus; stable but competitive market
IDYA,IDEAYA Biosciences Inc.,2.8B,500K,1.54,2.5% - 7%,$38.20 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,Darovasertib,None,Darovasertib Fast Track 2022,Phase 3 Data Readout Q1 2026,GSK (GSK) Pfizer (PFE),Oncology,Amgen (AMGN) Blueprint (BPMC),20 months,May 7 2025,EPS -0.65 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),7 (B+),BUY,USA,Oncology focus; promising pipeline; strong partnerships
IMCR,Immunocore Holdings plc,2.1B,600K,1.87,2.8% - 7.5%,$40.50 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,Biotechnology,KIMMTRAK,KIMMTRAK Jan 2022,KIMMTRAK Fast Track 2021,Phase 3 Data Readout IMC-M113V Q2 2026,None,Ocular Oncology,Aura (AURA),24 months,May 7 2025,EPS -0.45 +8% Beat Revenue 75.4M +10% Beat,Aug 5 2025 (est.),7 (B+),BUY,UK,KIMMTRAK commercial success; expanding oncology pipeline
IMMX,Immix Biopharma Inc.,80M,300K,2.10,3.5% - 9%,$2.10 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,IMX-110,None,IMX-110 Fast Track 2022,Phase 2 Data Readout Q3 2026,None,Oncology,Incyte (INCY) Merck (MRK),12 months,May 8 2025,EPS -0.25 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),HOLD,USA,High-risk oncology; limited cash runway; early-stage pipeline
IMNM,Immunome Inc.,600M,500K,1.76,2.8% - 7.5%,$15.80 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,IMM-101,None,None,Phase 1 Data Readout Q4 2025,None,Oncology,Amgen (AMGN) Regeneron (REGN),18 months,May 7 2025,EPS -0.35 -8% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),BUY,USA,Oncology focus; early-stage pipeline; stable cash position
IMVT,Immunovant Inc.,3.5B,700K,1.65,2.5% - 7%,$30.20 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Clinical,Healthcare,Biotechnology,Batoclimab,None,Batoclimab Fast Track 2023,Phase 3 Data Readout Q1 2026,None,Immunology,Argenx (ARGX) Regeneron (REGN),24 months,May 8 2025,EPS -0.55 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),7 (B+),BUY,USA,Immunology focus; promising phase 3 data; stable cash position
INBX,Inhibrx Inc.,450M,400K,1.92,3% - 8%,$14.50 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,INBRX-101,None,None,Phase 2 Data Readout Q4 2025,Sanofi (SNY),Rare Diseases,Amicus (FOLD) BioMarin (BMRN),15 months,May 7 2025,EPS -0.65 -12% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Rare disease focus; early-stage pipeline; Sanofi partnership
INCY,Incyte Corporation,13.8B,1.8M,1.45,1.8% - 5%,$65.20 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Stable,Commercial,Healthcare,Biotechnology,Jakafi Opzelura,Jakafi Feb 2011 Opzelura Sep 2021,Jakafi Fast Track 2010,Phase 3 Data Readout INCB54707 Q2 2026,None,Oncology Dermatology,Amgen (AMGN) Merck (MRK),N/A,May 7 2025,EPS 0.85 +12% Beat Revenue 1.0B +10% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,Jakafi strong commercial performance; Opzelura expanding; robust pipeline
INSM,Insmed Incorporated,10.2B,1.5M,1.54,2% - 6%,$68.50 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Arikayce,Arikayce Sep 2018,Arikayce Fast Track 2018,Phase 3 Data Readout TPIP Q1 2026,None,Pulmonary Diseases,Vertex (VRTX) Chiesi,24 months,May 8 2025,EPS -1.15 -8% Miss Revenue 80.7M +10% Beat,Aug 6 2025 (est.),8 (A-),BUY,USA,Arikayce commercialized; TPIP data key; strong growth potential
INVA,Innoviva Inc.,2.1B,600K,1.34,1.8% - 5%,$18.50 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,Biotechnology,Relvar Breo Ellipta,Relvar Breo Ellipta May 2013,None,Commercial Expansion Q4 2025,GSK (GSK),Respiratory,GSK (GSK) AstraZeneca (AZN),N/A,May 7 2025,EPS 0.35 +10% Beat Revenue 85.2M +8% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Respiratory focus; stable royalty revenue; financially sound
INZY,Inozyme Pharma Inc.,200M,300K,1.87,3% - 8%,$5.20 - 01:30 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,INZ-701,None,INZ-701 Fast Track 2022,Phase 3 Data Readout Q4 2025,None,Rare Diseases,Amicus (FOLD) BioMarin (BMRN),15 months,May 8 2025,EPS -0.45 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Rare disease focus; early-stage pipeline; moderate cash runway
IOVA,Iovance Biotherapeutics Inc.,2.4B,1.9M,1.76,2.8% - 7.5%,$10.80 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Amtagvi,Amtagvi Feb 2024,Amtagvi Fast Track 2023,Phase 3 Data Readout LN-145 Q2 2026,None,Oncology,Immunocore (IMCR) Bristol Myers (BMY),24 months,May 7 2025,EPS -0.35 +8% Beat Revenue 31.2M +15% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Amtagvi recently approved; commercial ramp-up critical; stable finances
ITCI,Intra-Cellular Therapies Inc.,7.5B,700K,1.45,2% - 6%,$78.50 - 01:30 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,Lumateperone,Caplyta Dec 2019,Caplyta Fast Track 2018,Phase 3 Data Readout ITI-214 Q1 2026,None,CNS Disorders,Axsome (AXSM) Jazz (JAZZ),N/A,May 7 2025,EPS -0.15 +12% Beat Revenue 144.8M +10% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,Caplyta strong commercial traction; expanding indications; financially stable
IVVD,Invivyd Inc.,150M,500K,2.01,3.5% - 9%,$1.80 - 01:30 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,INV104,None,INV104 Fast Track 2023,Phase 3 Data Readout Q3 2026,None,Antiviral Therapy,Atea (AVIR) Gilead (GILD),12 months,May 8 2025,EPS -0.25 -10% Miss Revenue 十大网赌正规网址下载 -5% Miss,Aug 6 2025 (est.),5 (B-),SELL,USA,High-risk antiviral focus; limited cash runway; early-stage pipeline
JANX,Janux Therapeutics Inc.,1.8B,600K,1.65,2.5% - 7%,$45.20 - 01:30 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,JANX007,None,None,Phase 1 Data Readout Q4 2025,None,Oncology,Amgen (AMGN) Merck (MRK),20 months,May 7 2025,EPS -0.35 -8% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),7 (B+),BUY,USA,Oncology focus; early-stage pipeline; promising data
JAZZ,Jazz Pharmaceuticals plc,6.8B,600K,1.34,1.8% - 5%,$110.20 - 01:55 PM EDT 06/10/2025,Yes - Large Purchase,Stable,Commercial,Healthcare,Biotechnology,Xyrem Xywav Epidiolex,Xyrem Jul 2002 Xywav Jul 2020 Epidiolex Jun 2018,Xywav Fast Track 2019,Phase 3 Data Readout Suvecaltamide Q4 2025,None,CNS Disorders,Harmony (HRMY) Axsome (AXSM),N/A,May 7 2025,EPS 4.25 +12% Beat Revenue 970.5M +8% Beat,Aug 5 2025 (est.),8 (A-),BUY,Ireland,Strong CNS portfolio; Xywav and Epidiolex driving growth; financially stable
JSPR,Jasper Therapeutics Inc.,150M,400K,1.92,3.2% - 8.5%,$2.80 - 01:55 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Briquilimab,None,None,Phase 2 Data Readout Q3 2026,None,Immunology,Regeneron (REGN) AnaptysBio (ANAB),12 months,May 8 2025,EPS -0.25 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),SELL,USA,High-risk immunology; limited cash runway; early-stage pipeline
KALV,KalVista Pharmaceuticals Inc.,350M,300K,1.76,2.8% - 7.5%,$12.50 - 01:55 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Sebetralstat,None,Sebetralstat Fast Track 2022,Phase 3 Data Readout Q4 2025,None,HAE,CSL Behring BioCryst (BCRX),15 months,May 7 2025,EPS -0.85 -8% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,HAE focus; sebetralstat pivotal data key; moderate cash runway
KNSA,Kiniksa Pharmaceuticals Ltd.,1.5B,500K,1.65,2.5% - 7%,$22.80 - 01:55 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Abiprubart,None,None,Phase 2 Data Readout Q2 2026,None,Immunology,Argenx (ARGX) Regeneron (REGN),20 months,May 7 2025,EPS -0.15 +10% Beat Revenue 85.2M +12% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Immunology focus; commercial-stage; stable cash position
KOD,Kodiak Sciences Inc.,200M,600K,2.01,3.5% - 9%,$3.20 - 01:55 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Tarcocimab,None,None,Phase 3 Data Readout Q4 2025,None,Ophthalmology,Regeneron (REGN) Apellis (APLS),12 months,May 8 2025,EPS -0.95 -12% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),SELL,USA,High-risk ophthalmology; limited cash runway; pivotal data critical
KROS,Keros Therapeutics Inc.,1.8B,400K,1.54,2.5% - 7%,$48.50 - 01:55 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,Elritercept,None,None,Phase 2 Data Readout Q1 2026,None,Hematology,Geron (GERN) Amgen (AMGN),20 months,May 7 2025,EPS -0.65 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),7 (B+),BUY,USA,Hematology focus; promising pipeline; stable cash position
KURA,Kura Oncology Inc.,1.2B,600K,1.87,2.8% - 7.5%,$20.80 - 01:55 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Ziftomenib,None,Ziftomenib Fast Track 2023,Phase 2 Data Readout Q4 2025,None,Oncology,Blueprint (BPMC) Incyte (INCY),18 months,May 8 2025,EPS -0.55 -8% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),BUY,USA,Oncology focus; ziftomenib data key; moderate cash runway
KTTA,Krystal Biotech Inc.,5.2B,300K,1.45,2% - 6%,$180.50 - 01:55 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,Vyjuvek,Vyjuvek May 2023,Vyjuvek Fast Track 2022,Phase 3 Data Readout KB707 Q2 2026,None,Gene Therapy,Abeona (ABEO) 4DMT (FDMT),N/A,May 7 2025,EPS 0.25 +15% Beat Revenue 70.3M +10% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,Vyjuvek commercial success; expanding gene therapy pipeline
KYMR,Kymera Therapeutics Inc.,2.5B,500K,1.65,2.5% - 7%,$38.20 - 01:55 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,KT-474,None,None,Phase 2 Data Readout Q1 2026,Sanofi (SNY),Immunology,Regeneron (REGN) AnaptysBio (ANAB),20 months,May 7 2025,EPS -0.75 -10% Miss Revenue 10.2M -5% Miss,Aug 5 2025 (est.),7 (B+),BUY,USA,Immunology focus; Sanofi partnership; stable cash position
LEGN,Legend Biotech Corporation,8.5B,1.1M,1.54,2% - 6%,$46.50 - 01:55 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Carvykti,Carvykti Feb 2022,Carvykti Fast Track 2021,Phase 3 Data Readout LB-100 Q3 2026,Janssen (JNJ),Cell Therapy,Allogene (ALLO) Arcellx (ACLX),24 months,May 8 2025,EPS -0.35 +8% Beat Revenue 95.4M +12% Beat,Aug 6 2025 (est.),8 (A-),BUY,China,Carvykti strong commercial traction; Janssen partnership; robust pipeline[](https://datafet.com/symbol-list.txt)
LENZ,Lenz Therapeutics Inc.,350M,200K,1.92,3.2% - 8.5%,$15.80 - 01:55 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,LNZ100,None,LNZ100 Fast Track 2023,Phase 3 Data Readout Q4 2025,None,Ophthalmology,Eyenovia (EYEN) Apellis (APLS),15 months,May 7 2025,EPS -0.45 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Ophthalmology focus; early-stage pipeline; moderate cash runway
LGND,Ligand Pharmaceuticals Inc.,1.8B,300K,1.45,2% - 6%,$98.50 - 01:55 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,Biotechnology,Captisol Technology,Multiple Captisol-based drugs,None,Commercial Expansion Q4 2025,Pfizer (PFE) Amgen (AMGN),Drug Delivery,Halozyme (HALO) Catalent (CTLT),N/A,May 8 2025,EPS 0.95 +10% Beat Revenue 45.7M +8% Beat,Aug 6 2025 (est.),7 (B+),BUY,USA,Captisol platform drives revenue; stable royalty stream; financially sound
LQDA,Liquidia Corporation,650M,700K,1.87,2.8% - 7.5%,$12.20 - 01:55 PM EDT 06/10/2025,No,Increase,Commercial,Healthcare,Biotechnology,Yutrepia,Yutrepia Nov 2024,Yutrepia Fast Track 2022,Commercial Expansion Q4 2025,None,Pulmonary Diseases,Insmed (INSM) United (UTHR),18 months,May 7 2025,EPS -0.25 +8% Beat Revenue 4.5M +10% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Yutrepia recently approved; commercial ramp-up critical; moderate cash runway
LRMR,Larimar Therapeutics Inc.,300M,400K,1.92,3.2% - 8.5%,$8.50 - 01:55 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Nomlabofusp,None,Nomlabofusp Fast Track 2023,Phase 2 Data Readout Q2 2026,None,Rare Diseases,Amicus (FOLD) BioMarin (BMRN),15 months,May 8 2025,EPS -0.35 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Rare disease focus; early-stage pipeline; moderate cash runway
LXRX,Lexicon Pharmaceuticals Inc.,350M,1.2M,2.01,3.5% - 9%,$2.10 - 01:55 PM EDT 06/10/2025,No,Decrease,Commercial,Healthcare,Biotechnology,Inpefa,Inpefa May 2023,Inpefa Fast Track 2022,Phase 3 Data Readout LX9211 Q3 2026,None,Cardiometabolic,AstraZeneca (AZN) Novo Nordisk (NVO),18 months,May 7 2025,EPS -0.15 -8% Miss Revenue 1.2M +5% Beat,Aug 5 2025 (est.),6 (B),HOLD,USA,Inpefa commercialized; LX9211 data key; moderate cash runway
LYEL,Lyell Immunopharma Inc.,200M,500K,1.76,3% - 8%,$2.80 - 01:55 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,LYL797,None,LYL797 Fast Track 2023,Phase 1 Data Readout Q4 2025,GSK (GSK),Cell Therapy,Allogene (ALLO) Arcellx (ACLX),15 months,May 8 2025,EPS -0.25 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),HOLD,USA,Cell therapy focus; early-stage pipeline; GSK partnership
MDGL,Madrigal Pharmaceuticals Inc.,5.5B,600K,1.65,2.5% - 7%,$280.50 - 01:55 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,Rezdiffra,Rezdiffra Mar 2024,Rezdiffra Fast Track 2022,Commercial Expansion Q4 2025,None,NASH,Akero (AKRO) 89bio (ETNB),24 months,May 7 2025,EPS -6.25 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),8 (A-),BUY,USA,Rezdiffra first-in-class NASH therapy; commercial ramp-up critical; strong cash position[](https://finance.yahoo.com/quote/BBIO/)[](https://www.evaluate.com/node/18476/amp)
MESO,Mesoblast Limited,1.2B,200K,1.87,2.8% - 7.5%,$7.50 - 01:55 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Remestemcel-L,None,Remestemcel-L Fast Track 2019,Phase 3 Data Readout Q2 2026,None,Cell Therapy,Allogene (ALLO) Celularity (CELU),18 months,May 8 2025,EPS -0.15 -8% Miss Revenue 7.2M -5% Miss,Aug 6 2025 (est.),6 (B),HOLD,Australia,Cell therapy focus; regulatory hurdles; moderate cash runway[](https://datafet.com/symbol-list.txt)
MGNX,MacroGenics Inc.,200M,1.1M,2.01,3.5% - 9%,$4.50 - 01:55 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Vobramitamab,None,None,Phase 2 Data Readout Q3 2026,Incyte (INCY),Oncology,Amgen (AMGN) Regeneron (REGN),12 months,May 7 2025,EPS -0.35 -12% Miss Revenue 10.8M -5% Miss,Aug 5 2025 (est.),5 (B-),SELL,USA,High-risk oncology; limited cash runway; early-stage pipeline[](https://datafet.com/symbol-list.txt)
MGTX,MeiraGTx Holdings plc,350M,300K,1.76,2.8% - 7.5%,$5.20 - 01:55 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,AAV-GAD,None,None,Phase 2 Data Readout Q4 2025,Janssen (JNJ),Gene Therapy,Krystal (KTTA) 4DMT (FDMT),15 months,May 8 2025,EPS -0.45 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Gene therapy focus; Janssen partnership; moderate cash runway
MGX,Metagenomi Inc.,150M,400K,1.92,3.2% - 8.5%,$4.80 - 01:55 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,MGX-001,None,None,Phase 1 Data Readout Q3 2026,Moderna (MRNA),Gene Editing,CRISPR (CRSP) Editas (EDIT),12 months,May 7 2025,EPS -0.35 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),5 (B-),SELL,USA,High-risk gene editing; limited cash runway; early-stage pipeline
MIRM,Mirum Pharmaceuticals Inc.,1.5B,500K,1.65,2.5% - 7%,$38.20 - 01:55 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Livmarli,Livmarli Nov 2020,Livmarli Fast Track 2020,Phase 3 Data Readout Volixibat Q1 2026,None,Rare Diseases,Amicus (FOLD) BioMarin (BMRN),24 months,May 7 2025,EPS -0.45 +8% Beat Revenue 77.5M +10% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Livmarli commercial success; volixibat data key; stable finances
MLYS,Mineralys Therapeutics Inc.,450M,300K,1.87,2.8% - 7.5%,$13.50 - 01:55 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Lorundrostat,None,None,Phase 3 Data Readout Q4 2025,None,Hypertension,AstraZeneca (AZN) Novartis (NVS),18 months,May 8 2025,EPS -0.55 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Hypertension focus; early-stage pipeline; moderate cash runway
MNKD,MannKind Corporation,1.4B,2.1M,1.76,2.8% - 7.5%,$5.80 - 01:55 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Afrezza,Afrezza Jun 2014,Afrezza Fast Track 2013,Commercial Expansion Q4 2025,United (UTHR),Diabetes,Novo Nordisk (NVO) Eli Lilly (LLY),N/A,May 7 2025,EPS 0.05 +12% Beat Revenue 65.3M +10% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Afrezza commercialized; expanding indications; financially stable[](https://db.cs.cmu.edu/files/data/stocks/history.txt)
MNMD,Mind Medicine (MindMed) Inc.,600M,1.5M,2.01,3.5% - 9%,$8.50 - 01:55 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,MM-120,None,MM-120 Fast Track 2022,Phase 3 Data Readout Q3 2026,None,CNS Disorders,Intra-Cellular (ITCI) Axsome (AXSM),18 months,May 8 2025,EPS -0.25 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Psychedelic therapy focus; early-stage pipeline; high-risk high-reward
MREO,Mereo BioPharma Group plc,600M,1.2M,1.76,2.8% - 7.5%,$4.50 - 01:58 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Clinical,Healthcare,Biotechnology,Setrusumab,None,Setrusumab Fast Track 2022,Phase 3 Data Readout Q4 2025,Ultragenyx (RARE),Rare Diseases,Amicus (FOLD) BioMarin (BMRN),18 months,May 7 2025,EPS -0.10 -8% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,UK,Rare disease focus; setrusumab pivotal data key; Ultragenyx partnership[](https://investorshub.advfn.com/Biotech-Values-1418)
MRNS,Marinus Pharmaceuticals Inc.,80M,600K,2.01,3.5% - 9%,$1.40 - 01:58 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Ganaxolone,Ztalmy Mar 2022,Ganaxolone Fast Track 2021,Phase 3 Data Readout Q3 2026,None,CNS Disorders,Jazz (JAZZ) Axsome (AXSM),12 months,May 8 2025,EPS -0.65 -10% Miss Revenue 8.2M -5% Miss,Aug 6 2025 (est.),5 (B-),SELL,USA,Ztalmy commercialized; high-risk pipeline; limited cash runway[](https://finance.yahoo.com/quote/BTAI/)[](https://github.com/pthoang/TDT4310_project/blob/master/FinNum_training_rebuilded.csv)
MRSN,Mersana Therapeutics Inc.,150M,1.1M,1.92,3.2% - 8.5%,$2.10 - 01:58 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,XMT-1660,None,None,Phase 1 Data Readout Q4 2025,Janssen (JNJ),Oncology,Amgen (AMGN) Incyte (INCY),15 months,May 7 2025,EPS -0.25 -10% Miss Revenue 10.5M -5% Miss,Aug 5 2025 (est.),5 (B-),HOLD,USA,Oncology focus; early-stage pipeline; Janssen partnership[](https://finance.yahoo.com/quote/BTAI/)
MRUS,Merus N.V.,2.5B,500K,1.65,2.5% - 7%,$55.80 - 01:58 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,Zenocutuzumab,None,Zenocutuzumab Fast Track 2021,Phase 2 Data Readout Q1 2026,Incyte (INCY) Lilly (LLY),Oncology,Regeneron (REGN) Blueprint (BPMC),20 months,May 8 2025,EPS -0.85 -8% Miss Revenue 10.2M +5% Beat,Aug 6 2025 (est.),7 (B+),BUY,Netherlands,Oncology focus; zenocutuzumab promising; stable cash position
MTEM,Molecular Templates Inc.,80M,300K,2.10,3.5% - 9%,$1.20 - 01:58 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,MT-6402,None,None,Phase 1 Data Readout Q3 2026,None,Oncology,MacroGenics (MGNX) Amgen (AMGN),12 months,May 7 2025,EPS -0.15 -12% Miss Revenue 7.8M -5% Miss,Aug 5 2025 (est.),5 (B-),SELL,USA,High-risk oncology; limited cash runway; early-stage pipeline[](https://github.com/pthoang/TDT4310_project/blob/master/FinNum_training_rebuilded.csv)
NAMS,NewAmsterdam Pharma Company N.V.,1.8B,400K,1.54,2.5% - 7%,$20.50 - 01:58 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,Obicetrapib,None,None,Phase 3 Data Readout Q4 2025,None,Cardiovascular,Pfizer (PFE) Amgen (AMGN),20 months,May 8 2025,EPS -0.45 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),7 (B+),BUY,Netherlands,Cardiovascular focus; obicetrapib pivotal data key; stable cash position
NAUT,Nautilus Biotechnology Inc.,200M,200K,1.76,2.8% - 7.5%,$2.80 - 01:58 PM EDT 06/10/2025,No,Stable,Pre-Clinical,Healthcare,Biotechnology,N/A,None,None,None,None,Proteomics,Seer (SEER) Somalogic,15 months,May 7 2025,EPS -0.15 -8% Miss Revenue 2.3M -5% Miss,Aug 5 2025 (est.),5 (B-),HOLD,USA,Proteomics platform; pre-clinical stage; moderate cash runway
NBTX,Nanobiotix S.A.,350M,150K,1.87,3% - 8%,$6.50 - 01:58 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,NBTXR3,None,NBTXR3 Fast Track 2022,Phase 3 Data Readout Q2 2026,None,Oncology,Curis (CRIS) Cullinan (CGEM),15 months,May 8 2025,EPS -0.35 -10% Miss Revenue 5.4M -5% Miss,Aug 6 2025 (est.),6 (B),HOLD,France,Oncology focus; NBTXR3 pivotal data key; moderate cash runway[](https://finance.yahoo.com/quote/NBTX/?ltr=1)
NRIX,Nurix Therapeutics Inc.,1.2B,600K,1.92,3.2% - 8.5%,$20.80 - 01:58 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,NX-5948,None,None,Phase 1 Data Readout Q4 2025,Gilead (GILD) Sanofi (SNY),Oncology,Kura (KURA) Blueprint (BPMC),18 months,May 7 2025,EPS -0.65 -8% Miss Revenue 12.3M +5% Beat,Aug 5 2025 (est.),6 (B),BUY,USA,Oncology focus; early-stage pipeline; strong partnerships
NTLA,Intellia Therapeutics Inc.,2.1B,1.4M,1.76,2.8% - 7.5%,$22.50 - 01:58 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Clinical,Healthcare,Biotechnology,NTLA-2001,None,NTLA-2001 Fast Track 2022,Phase 3 Data Readout Q1 2026,Regeneron (REGN),Gene Editing,CRISPR (CRSP) Editas (EDIT),18 months,May 8 2025,EPS -1.35 -10% Miss Revenue 7.8M -5% Miss,Aug 6 2025 (est.),7 (B+),BUY,USA,Gene editing focus; NTLA-2001 promising; Regeneron partnership
NUVB,Nuvation Bio Inc.,650M,500K,1.65,2.5% - 7%,$3.20 - 01:58 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Talazoparib,None,None,Phase 2 Data Readout Q4 2025,None,Oncology,Amgen (AMGN) Pfizer (PFE),18 months,May 7 2025,EPS -0.15 -8% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Oncology focus; early-stage pipeline; moderate cash runway
NUVL,Nuvalent Inc.,5.2B,400K,1.54,2% - 6%,$80.50 - 01:58 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Clinical,Healthcare,Biotechnology,NVL-520,None,None,Phase 2 Data Readout Q2 2026,None,Oncology,Blueprint (BPMC) Kura (KURA),24 months,May 8 2025,EPS -0.75 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),8 (A-),BUY,USA,Oncology focus; promising pipeline; strong cash position
NVO,Novo Nordisk A/S,580B,1.8M,1.23,1.8% - 5%,$130.20 - 01:58 PM EDT 06/10/2025,Yes - Large Purchase,Stable,Commercial,Healthcare,Biotechnology,Ozempic Wegovy Rybelsus,Ozempic Mar 2017 Wegovy Jun 2021 Rybelsus Sep 2019,Ozempic Fast Track 2016,Phase 3 Data Readout CagriSema Q1 2026,None,Diabetes Obesity,Eli Lilly (LLY) Amgen (AMGN),N/A,May 7 2025,EPS 0.85 +15% Beat Revenue 10.2B +12% Beat,Aug 5 2025 (est.),9 (A),STRONG BUY,Denmark,Ozempic and Wegovy market leaders; robust pipeline; financially stable[](https://finance.yahoo.com/quote/NVO/)
OABI,OmniAb Inc.,600M,300K,1.45,2% - 6%,$5.20 - 01:58 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,N/A,None,None,None,Lilly (LLY) Genmab (GMAB),Antibody Discovery,Ligand (LGND) Amgen (AMGN),18 months,May 8 2025,EPS -0.15 -8% Miss Revenue 7.5M +5% Beat,Aug 6 2025 (est.),6 (B),HOLD,USA,Antibody platform; early-stage partnerships; moderate cash runway
OCUL,Ocular Therapeutix Inc.,650M,700K,1.87,2.8% - 7.5%,$8.50 - 01:58 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Dextenza,Dextenza Dec 2018,Dextenza Fast Track 2018,Phase 3 Data Readout AXPAXLI Q4 2025,None,Ophthalmology,Eyenovia (EYEN) Apellis (APLS),18 months,May 7 2025,EPS -0.25 +8% Beat Revenue 15.3M +10% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Dextenza commercialized; AXPAXLI data key; moderate cash runway
OLMA,Olema Pharmaceuticals Inc.,600M,500K,1.92,3.2% - 8.5%,$12.80 - 01:58 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,Palazestrant,None,None,Phase 3 Data Readout Q1 2026,None,Oncology,Arvinas (ARVN) Mersana (MRSN),18 months,May 8 2025,EPS -0.55 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Oncology focus; early-stage pipeline; moderate cash runway
OMER,Omeros Corporation,200M,600K,2.01,3.5% - 9%,$3.50 - 01:58 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,Narsoplimab,None,Narsoplimab Fast Track 2020,Phase 3 Data Readout Q4 2025,None,Immunology,KalVista (KALV) CSL Behring,12 months,May 7 2025,EPS -0.65 -12% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),5 (B-),SELL,USA,High-risk immunology; limited cash runway; regulatory hurdles
ORIC,ORIC Pharmaceuticals Inc.,350M,400K,1.76,2.8% - 7.5%,$8.50 - 01:58 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,ORIC-114,None,None,Phase 1 Data Readout Q4 2025,Pfizer (PFE),Oncology,Kura (KURA) Nurix (NRIX),15 months,May 8 2025,EPS -0.45 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Oncology focus; early-stage pipeline; Pfizer partnership[](https://finance.yahoo.com/quote/NBTX/?ltr=1)
OSCR,Oscar Health Inc.,4.8B,1.5M,1.54,2% - 6%,$20.50 - 01:58 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Health Insurance,N/A,N/A,N/A,Commercial Expansion Q4 2025,None,Health Insurance,UnitedHealth (UNH) Cigna (CI),N/A,May 7 2025,EPS 0.15 +12% Beat Revenue 2.1B +10% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Health insurance focus; strong growth; not a traditional biotech
OSMT,Osmotica Pharmaceuticals plc,150M,200K,1.87,3% - 8%,$2.20 - 01:58 PM EDT 06/10/2025,No,Decrease,Commercial,Healthcare,Biotechnology,Upneeq,Upneeq Jul 2020,Upneeq Fast Track 2020,Commercial Expansion Q4 2025,None,Ophthalmology,Ocular (OCUL) Eyenovia (EYEN),15 months,May 8 2025,EPS -0.15 -8% Miss Revenue 10.2M +5% Beat,Aug 6 2025 (est.),6 (B),HOLD,USA,Upneeq commercialized; niche ophthalmology market; moderate cash runway
PBYI,Puma Biotechnology Inc.,200M,400K,2.01,3.5% - 9%,$3.80 - 01:58 PM EDT 06/10/2025,No,Stable,Commercial,Healthcare,Biotechnology,Nerlynx,Nerlynx Jul 2017,Nerlynx Fast Track 2016,Phase 2 Data Readout Q3 2026,Pfizer (PFE),Oncology,Mersana (MRSN) MacroGenics (MGNX),N/A,May 7 2025,EPS 0.05 +10% Beat Revenue 45.3M +8% Beat,Aug 5 2025 (est.),6 (B),HOLD,USA,Nerlynx commercialized; limited growth potential; stable finances
PCVX,Vaxcyte Inc.,4.5B,600K,1.65,2.5% - 7%,$75.20 - 01:58 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Clinical,Healthcare,Biotechnology,VAX-24,None,VAX-24 Fast Track 2023,Phase 3 Data Readout Q1 2026,None,Vaccines,Pfizer (PFE) Moderna (MRNA),24 months,May 8 2025,EPS -0.95 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),8 (A-),BUY,USA,Vaccine focus; VAX-24 promising; strong cash position
PDSB,PDS Biotechnology Corporation,200M,700K,1.92,3.2% - 8.5%,$3.50 - 01:58 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,PDS0101,None,PDS0101 Fast Track 2021,Phase 2 Data Readout Q4 2025,Merck (MRK),Oncology,IO Biotech (IOBT) Mersana (MRSN),15 months,May 7 2025,EPS -0.35 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Oncology focus; early-stage pipeline; Merck partnership[](https://investorshub.advfn.com/Biotech-Values-1418)
PGEN,Precigen Inc.,150M,1.2M,2.01,3.5% - 9%,$1.40 - 02:01 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,PRGN-2012,None,PRGN-2012 Fast Track 2022,Phase 2 Data Readout Q4 2025,None,Oncology,IO Biotech (IOBT) PDS Biotech (PDSB),12 months,May 7 2025,EPS -0.10 -10% Miss Revenue 1.2M -5% Miss,Aug 5 2025 (est.),5 (B-),SELL,USA,High-risk oncology; limited cash runway; early-stage pipeline
PHAR,Pharming Group N.V.,350M,200K,1.76,2.8% - 7.5%,$8.50 - 02:01 PM EDT 06/10/2025,No,Stable,Commercial,Healthcare,Biotechnology,Leniolisib,Joenja Apr 2023,Joenja Fast Track 2022,Commercial Expansion Q4 2025,None,Rare Diseases,Amicus (FOLD) BioMarin (BMRN),18 months,May 8 2025,EPS -0.05 +8% Beat Revenue 75.3M +10% Beat,Aug 6 2025 (est.),6 (B),HOLD,Netherlands,Joenja commercialized; rare disease focus; moderate cash runway
PHAT,Phathom Pharmaceuticals Inc.,600M,500K,1.87,3% - 8%,$12.80 - 02:01 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Voquezna,Voquezna Aug 2024,Voquezna Fast Track 2023,Commercial Expansion Q4 2025,None,Gastroenterology,Takeda (TAK) Ironwood (IRWD),18 months,May 7 2025,EPS -0.65 -8% Miss Revenue 7.5M +12% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Voquezna recently approved; commercial ramp-up critical; moderate cash runway
PHVS,Pharvaris N.V.,450M,300K,1.65,2.5% - 7%,$18.50 - 02:01 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Deucrictibant,None,Deucrictibant Fast Track 2023,Phase 3 Data Readout Q1 2026,None,HAE,KalVista (KALV) CSL Behring,20 months,May 8 2025,EPS -0.55 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,Netherlands,HAE focus; deucrictibant pivotal data key; stable cash position
PLRX,Pliant Therapeutics Inc.,650M,400K,1.92,3.2% - 8.5%,$12.20 - 02:01 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,Bexotegrast,None,Bexotegrast Fast Track 2022,Phase 2b Data Readout Q4 2025,None,Fibrosis,FibroGen (FGEN) 89bio (ETNB),18 months,May 7 2025,EPS -0.75 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),7 (B+),BUY,USA,Fibrosis focus; bexotegrast promising; stable cash position[](https://finance.yahoo.com/quote/RNA/)
PLUR,Pluristem Therapeutics Inc.,80M,200K,2.10,3.5% - 9%,$5.50 - 02:01 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,PLX-PAD,None,None,Phase 3 Data Readout Q3 2026,None,Regenerative Medicine,Celularity (CELU) Mesoblast (MESO),12 months,May 8 2025,EPS -0.25 -12% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),SELL,Israel,High-risk regenerative medicine; limited cash runway; early-stage pipeline
PRME,Prime Medicine Inc.,350M,500K,1.76,2.8% - 7.5%,$5.80 - 02:01 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,PM359,None,None,Phase 1 Data Readout Q4 2025,None,Gene Editing,Intellia (NTLA) Editas (EDIT),15 months,May 7 2025,EPS -0.35 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Gene editing focus; early-stage pipeline; moderate cash runway
PRTA,Prothena Corporation plc,1.2B,600K,1.65,2.5% - 7%,$22.50 - 02:01 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,PRX012,None,None,Phase 2 Data Readout Q2 2026,BMS (BMY),Neurodegenerative Diseases,Denali (DNLI) Alector (ALEC),18 months,May 8 2025,EPS -0.95 -8% Miss Revenue 2.3M -5% Miss,Aug 6 2025 (est.),6 (B),BUY,USA,Neuro focus; PRX012 promising; BMS partnership
PTCT,PTC Therapeutics Inc.,2.5B,700K,1.54,2% - 6%,$35.80 - 02:01 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,Biotechnology,Emflaza Upstaza,Emflaza Apr 2017 Upstaza (EU Approved 2022),Emflaza Fast Track 2016,Phase 3 Data Readout Vatiquinone Q1 2026,None,Rare Diseases,Amicus (FOLD) BioMarin (BMRN),N/A,May 7 2025,EPS -1.25 -10% Miss Revenue 175.4M +8% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Emflaza commercialized; Upstaza US approval pending; stable finances
PTGX,Protagonist Therapeutics Inc.,1.8B,500K,1.87,2.8% - 7.5%,$35.20 - 02:01 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,Rusfertide,None,Rusfertide Fast Track 2023,Phase 3 Data Readout Q4 2025,Takeda (TAK),Hematology,Keros (KROS) Geron (GERN),20 months,May 8 2025,EPS -0.45 -8% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),7 (B+),BUY,USA,Hematology focus; rusfertide pivotal data key; stable cash position
QURE,uniQure N.V.,350M,600K,1.92,3.2% - 8.5%,$5.50 - 02:01 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,AMT-130,None,AMT-130 Fast Track 2021,Phase 1/2 Data Readout Q3 2026,CSL Behring,Gene Therapy,Krystal (KTTA) 4DMT (FDMT),15 months,May 7 2025,EPS -1.15 -12% Miss Revenue 2.5M -5% Miss,Aug 5 2025 (est.),6 (B),HOLD,Netherlands,Gene therapy focus; AMT-130 data key; CSL partnership
RARE,Ultragenyx Pharmaceutical Inc.,4.2B,700K,1.65,2.5% - 7%,$48.50 - 02:01 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,Mepsevii Crysvita Dojolvi,Mepsevii Nov 2017 Crysvita Apr 2018 Dojolvi Jun 2020,Mepsevii Fast Track 2017,Phase 3 Data Readout UX701 Q2 2026,Mereo (MREO),Rare Diseases,Amicus (FOLD) BioMarin (BMRN),N/A,May 8 2025,EPS -1.85 -8% Miss Revenue 125.3M +10% Beat,Aug 6 2025 (est.),8 (A-),BUY,USA,Strong rare disease portfolio; multiple approved drugs; financially stable
RCKT,Rocket Pharmaceuticals Inc.,1.5B,600K,1.76,2.8% - 7.5%,$20.80 - 02:01 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,RP-L201,None,RP-L201 Fast Track 2021,Phase 2 Data Readout Q1 2026,None,Gene Therapy,uniQure (QURE) Krystal (KTTA),20 months,May 7 2025,EPS -0.75 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),7 (B+),BUY,USA,Gene therapy focus; RP-L201 promising; stable cash position[](https://investorshub.advfn.com/Biotech-Values-1418)
RCUS,Arcus Biosciences Inc.,1.2B,800K,1.87,3% - 8%,$15.80 - 02:01 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Etrumadenant,None,None,Phase 2 Data Readout Q4 2025,Gilead (GILD) Taiho Oncology,Oncology,Amgen (AMGN) Merck (MRK),18 months,May 8 2025,EPS -0.95 -8% Miss Revenue 45.2M +12% Beat,Aug 6 2025 (est.),6 (B),HOLD,USA,Oncology focus; Gilead partnership; moderate cash runway
REGN,Regeneron Pharmaceuticals Inc.,115B,500K,1.23,1.8% - 5%,$1050.20 - 02:01 PM EDT 06/10/2025,Yes - Large Purchase,Stable,Commercial,Healthcare,Biotechnology,Eylea Dupixent,Eylea Aug 2011 Dupixent Mar 2017,Dupixent Fast Track 2016,Phase 3 Data Readout Odronextamab Q1 2026,Sanofi (SNY) Bayer,Ophthalmology Immunology,Amgen (AMGN) Roche (RHHBY),N/A,May 7 2025,EPS 10.25 +15% Beat Revenue 3.2B +10% Beat,Aug 5 2025 (est.),9 (A),STRONG BUY,USA,Eylea and Dupixent market leaders; robust pipeline; financially stable[](https://bullishbears.com/biotech-stocks-list/)
REPL,Replimune Group Inc.,350M,700K,1.92,3.2% - 8.5%,$8.50 - 02:01 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,RP1,None,None,Phase 2 Data Readout Q4 2025,Regeneron (REGN),Oncology,IO Biotech (IOBT) PDS Biotech (PDSB),15 months,May 8 2025,EPS -0.85 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Oncology focus; early-stage pipeline; Regeneron partnership
RGNX,REGENXBIO Inc.,600M,600K,1.76,2.8% - 7.5%,$12.80 - 02:01 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Clinical,Healthcare,Biotechnology,RGX-121,None,RGX-121 Fast Track 2021,Phase 3 Data Readout Q2 2026,None,Gene Therapy,uniQure (QURE) Rocket (RCKT),18 months,May 7 2025,EPS -1.25 -8% Miss Revenue 15.3M -5% Miss,Aug 5 2025 (est.),6 (B),HOLD,USA,Gene therapy focus; RGX-121 data key; moderate cash runway
RIGL,Rigel Pharmaceuticals Inc.,200M,1.1M,2.01,3.5% - 9%,$1.20 - 02:01 PM EDT 06/10/2025,No,Decrease,Commercial,Healthcare,Biotechnology,Rezlidhia,Rezlidhia Dec 2022,Rezlidhia Fast Track 2022,Commercial Expansion Q4 2025,None,Hematology,Geron (GERN) Jazz (JAZZ),18 months,May 8 2025,EPS -0.05 +8% Beat Revenue 36.4M +10% Beat,Aug 6 2025 (est.),6 (B),HOLD,USA,Rezlidhia commercialized; niche hematology market; moderate cash runway
RLAY,Relay Therapeutics Inc.,650M,700K,1.87,3% - 8%,$8.50 - 02:01 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,RLY-2608,None,None,Phase 1 Data Readout Q4 2025,None,Oncology,Nuvalent (NUVL) Kura (KURA),15 months,May 7 2025,EPS -0.75 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Oncology focus; early-stage pipeline; moderate cash runway
RNA,Avidity Biosciences Inc.,2.5B,600K,1.76,2.8% - 7.5%,$38.50 - 02:01 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Clinical,Healthcare,Biotechnology,AOC 1001,None,AOC 1001 Fast Track 2022,Phase 2 Data Readout Q1 2026,BMS (BMY),Rare Diseases,Amicus (FOLD) Ultragenyx (RARE),20 months,May 8 2025,EPS -0.65 -8% Miss Revenue 10.5M +5% Beat,Aug 6 2025 (est.),7 (B+),BUY,USA,Rare disease focus; AOC 1001 promising; stable cash position[](https://finance.yahoo.com/quote/RNA/)
RPRX,Royalty Pharma plc,12.5B,2.1M,1.34,1.8% - 5%,$28.50 - 02:01 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,Biotechnology,N/A,Multiple Royalty Agreements,None,Commercial Expansion Q4 2025,Pfizer (PFE) Merck (MRK),Royalty Financing,Ligand (LGND) Halozyme (HALO),N/A,May 7 2025,EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,Strong royalty portfolio; stable revenue stream; financially sound
RVMD,Revolution Medicines Inc.,3.5B,700K,1.65,2.5% - 7%,$45.20 - 02:01 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,RMC-6236,None,None,Phase 1 Data Readout Q4 2025,None,Oncology,Kura (KURA) Nuvalent (NUVL),24 months,May 8 2025,EPS -0.85 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),7 (B+),BUY,USA,Oncology focus; early-stage pipeline; strong cash position[](https://investorshub.advfn.com/Biotech-Values-1418)
RXRX,Recursion Pharmaceuticals Inc.,650M,1.5M,1.92,3.2% - 8.5%,$8.80 - 02:01 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,REC-994,None,None,Phase 2 Data Readout Q3 2026,None,AI-Driven Drug Discovery,Exscientia (EXAI) Absci (ABSI),18 months,May 7 2025,EPS -0.45 -8% Miss Revenue 15.2M +5% Beat,Aug 5 2025 (est.),6 (B),HOLD,USA,AI-driven platform; early-stage pipeline; moderate cash runway
RYTM,Rhythm Pharmaceuticals Inc.,2.8B,500K,1.54,2% - 6%,$48.50 - 02:01 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,Imcivree,Imcivree Nov 2020,Imcivree Fast Track 2020,Phase 3 Data Readout LB54640 Q2 2026,None,Rare Diseases,Amicus (FOLD) Ultragenyx (RARE),24 months,May 8 2025,EPS -0.75 +8% Beat Revenue 28.4M +10% Beat,Aug 6 2025 (est.),8 (A-),BUY,USA,Imcivree commercial success; expanding pipeline; stable finances
RZLT,Rezolute Inc.,200M,300K,2.01,3.5% - 9%,$3.80 - 02:01 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,RZ358,None,None,Phase 2 Data Readout Q4 2025,None,Rare Diseases,Amicus (FOLD) BioMarin (BMRN),15 months,May 7 2025,EPS -0.35 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Rare disease focus; early-stage pipeline; moderate cash runway[](https://www.biopharmcatalyst.com/news/2024/rezolute-rzlt-phase-2-data-pliant-plrx-preclinical-data)
SAGE,Sage Therapeutics Inc.,650M,800K,1.87,2.8% - 7.5%,$10.80 - 02:15 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,Biotechnology,Zuranolone,Zulresso Mar 2019 Zurzuvae Aug 2023,Zuranolone Fast Track 2022,Phase 3 Data Readout SAGE-324 Q2 2026,Biogen (BIIB),CNS Disorders,Jazz (JAZZ) Axsome (AXSM),18 months,May 7 2025,EPS -1.65 -8% Miss Revenue 12.3M +5% Beat,Aug 5 2025 (est.),6 (B),HOLD,USA,Zurzuvae commercializing; CNS focus; Biogen partnership key
SANA,Sana Biotechnology Inc.,1.5B,700K,1.92,3.2% - 8.5%,$6.80 - 02:15 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,SC291,None,None,Phase 1 Data Readout Q4 2025,None,Cell Therapy,Allogene (ALLO) Lyell (LYEL),20 months,May 8 2025,EPS -0.35 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Cell therapy focus; early-stage pipeline; stable cash position
SGMO,Sangamo Therapeutics Inc.,200M,1.5M,2.01,3.5% - 9%,$0.80 - 02:15 PM EDT 06/10/2025,No,10% Decrease,Clinical,Healthcare,Biotechnology,SB-525,None,None,Phase 3 Data Readout Q4 2025,Pfizer (PFE),Gene Therapy,uniQure (QURE) Rocket (RCKT),12 months,May 6 2025,EPS -0.15 -0% Miss Revenue N/A,Aug 7 2025 (est.),5 (B-,SELL,USA),High-risk gene therapy; limited cash runway; Pfizer partnership
SLDB,Solid Biosciences Inc.,350M,400K,1.76,2.8% - 7.5%,$3.50 - 02:15 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,SGT-003,None,SGT-003 Fast Track 2024,Phase 1/2 Data Readout Q1 2025,None,Gene Therapy,Ultragenyx (RARE) Rocket (RCKT),18 months,May 8 2025,EPS -0.65 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Gene therapy focus; early-stage pipeline; moderate cash runway
SLNO,Soleno Therapeutics Inc.,2.8B,600K,1.65,2.5% - 7%,$48.50 - 02:15 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Clinical,Healthcare,Biotechnology,DCCR,None,DCCR Fast Track 2023,FDA Decision Q3 2025,None,Rare Diseases,Rhythm (RYTM) Amicus (FOLD),24 months,May 7 2025,EPS -0.25 +8% Beat Revenue 0.0M N/A,Aug 5 2025 (est.),7 (B+),BUY,USA,DCCR nearing approval; rare disease focus; strong cash position[](https://finance.yahoo.com/quote/SLNO/)
SMMT,Summit Therapeutics Inc.,2.5B,1.2M,1.87,3% - 8%,$12.80 - 02:15 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,Ivonescimab,None,None,Phase 3 Data Readout Q2 2026,Akeso Inc.,Oncology,Amgen (AMGN) Merck (MRK),20 months,May 8 2025,EPS -0.05 -8% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),7 (B+),BUY,USA,Oncology focus; ivonescimab promising; Akeso partnership
SPRY,ARS Pharmaceuticals Inc.,650M,500K,1.54,2% - 6%,$10.50 - 02:15 PM EDT 06/10/2025,No,Stable,Commercial,Healthcare,Biotechnology,Neffy,Neffy Aug 2024,Neffy Fast Track 2023,Commercial Expansion Q4 2025,None,Allergy,KalVista (KALV) CSL Behring,18 months,May 7 2025,EPS -0.15 +10% Beat Revenue 5.3M +12% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Neffy recently approved; commercial ramp-up critical; stable finances
STOK,Stoke Therapeutics Inc.,600M,400K,1.85,3.2% - 8.5%,$15.20 - 02:15 PM EDT 06/10/2025,25% Increase, Yes - Moderate Purchase,Clinical,Healthcare,Biotechnology,STK-001,None,STK-001 Fast Track 2021,Phase 2 Data Readout Q1 2025,None,CNS Disorders,Sage (SAGE) Jazz (JAZZ),20 months,May 8 2025,EPS -0.55 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),BUY,USA,CNS focus; STK-001 promising; stable cash position
SYRE,Spyre Therapeutics Inc.,1.2B,300K,1.76,2.8% - 7.5%,$28.50 - 02:15 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,SPY001,None,None,Phase 1 Data Readout Q4 2025,None,Immunology,Regeneron (REGN) AnaptysBio (ANAB),18 months,May 7 2025,EPS -0.85 -8% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Immunology focus; early-stage pipeline; moderate cash runway
TCRX,TScan Therapeutics Inc.,350M,200K,1.87,3% - 8%,$6.80 - 02:15 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,TSC-100,None,None,Phase 1 Data Readout Q3 2026,None,Cell Therapy,Lyell (LYEL) Allogene (ALLO),15 months,May 8 2025,EPS -0.35 -10% Miss Revenue 2.3M -5% Miss,Aug 6 2025 (est.),6 (B),HOLD,USA,Cell therapy focus; early-stage pipeline; moderate cash runway[](https://www.benzinga.com/general/biotech/21/09/22947673/the-daily-biotech-pulse-lilly-regeneron-ink-covid-19-drug-deal-with-us-regulatory-setback-for-cal)
TGTX,TG Therapeutics Inc.,2.8B,1.5M,1.65,2.5% - 7%,$20.50 - 02:15 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Commercial,Healthcare,Biotechnology,Briumvi,Briumvi Dec 2022,Briumvi Fast Track 2022,Commercial Expansion Q4 2025,None,Immunology,Argenx (ARGX) Regeneron (REGN),N/A,May 7 2025,EPS 0.05 +12% Beat Revenue 65.4M +10% Beat,Aug 5 2025 (est.),8 (A-),BUY,USA,Briumvi strong commercial traction; expanding indications; financially stable
THRX,Theseus Pharmaceuticals Inc.,150M,200K,1.92,3.2% - 8.5%,$4.50 - 02:15 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,THE-630,None,None,Phase 1 Data Readout Q4 2025,None,Oncology,Kura (KURA) Nuvalent (NUVL),12 months,May 8 2025,EPS -0.25 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),SELL,USA,High-risk oncology; limited cash runway; early-stage pipeline
TNGX,Tango Therapeutics Inc.,350M,400K,1.76,2.8% - 7.5%,$8.50 - 02:15 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,TNG908,None,None,Phase 1 Data Readout Q3 2026,None,Oncology,Relay (RLAY) Nuvalent (NUVL),15 months,May 7 2025,EPS -0.35 -8% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Oncology focus; early-stage pipeline; moderate cash runway
TRML,Tourmaline Bio Inc.,650M,300K,1.65,2.5% - 7%,$15.80 - 02:15 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,TOUR006,None,None,Phase 2 Data Readout Q1 2026,None,Immunology,Argenx (ARGX) Regeneron (REGN),20 months,May 8 2025,EPS -0.65 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),7 (B+),BUY,USA,Immunology focus; TOUR006 promising; stable cash position
VKTX,Viking Therapeutics Inc.,5.5B,1.8M,1.54,2% - 6%,$65.20 - 02:15 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Clinical,Healthcare,Biotechnology,VK2735,None,VK2735 Fast Track 2024,Phase 3 Data Readout Q1 2026,None,Obesity,Novo Nordisk (NVO) Eli Lilly (LLY),24 months,May 7 2025,EPS -0.25 -8% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),8 (A-),BUY,USA,VK2735 promising in obesity; strong cash position; high market interest
VRDN,Viridian Therapeutics Inc.,650M,500K,1.87,3% - 8%,$12.80 - 02:15 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Clinical,Healthcare,Biotechnology,VRDN-001,None,VRDN-001 Fast Track 2023,Phase 3 Data Readout Q4 2025,None,Immunology,Argenx (ARGX) Regeneron (REGN),18 months,May 8 2025,EPS -0.45 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),7 (B+),BUY,USA,Immunology focus; VRDN-001 pivotal data key; moderate cash runway
VRNA,Verona Pharma plc,2.2B,600K,1.65,2.5% - 7%,$28.50 - 02:15 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Ensifentrine,Ohtuvayre Jun 2024,Ohtuvayre Fast Track 2023,Commercial Expansion Q4 2025,None,Respiratory,Insmed (INSM) Chiesi,24 months,May 7 2025,EPS -0.35 +8% Beat Revenue 0.0M N/A,Aug 5 2025 (est.),7 (B+),BUY,UK,Ohtuvayre recently approved; commercial ramp-up critical; stable finances
VSTM,Verastem Inc.,200M,700K,2.01,3.5% - 9%,$3.20 - 02:15 PM EDT 06/10/2025,No,Stable,Clinical,Healthcare,Biotechnology,Avutometinib,None,None,Phase 2 Data Readout Q4 2025,None,Oncology,Kura (KURA) Relay (RLAY),15 months,May 8 2025,EPS -0.25 -10% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),6 (B),HOLD,USA,Oncology focus; early-stage pipeline; moderate cash runway
VYGR,Voyager Therapeutics Inc.,350M,400K,1.76,2.8% - 7.5%,$8.50 - 02:15 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Clinical,Healthcare,Biotechnology,VY-TAU01,None,None,Phase 1 Data Readout Q3 2026,Neurocrine (NBIX),Neurodegenerative Diseases,Denali (DNLI) Alector (ALEC),18 months,May 7 2025,EPS -0.45 -8% Miss Revenue 12.3M +5% Beat,Aug 5 2025 (est.),6 (B),HOLD,USA,Neuro focus; early-stage pipeline; Neurocrine partnership
WVE,Wave Life Sciences Ltd.,650M,600K,1.92,3.2% - 8.5%,$8.80 - 02:15 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,WVE-006,None,WVE-006 Fast Track 2024,Phase 2 Data Readout Q1 2026,GSK (GSK),Rare Diseases,Amicus (FOLD) Ultragenyx (RARE),18 months,May 8 2025,EPS -0.25 -10% Miss Revenue 15.2M -5% Miss,Aug 6 2025 (est.),7 (B+),BUY,USA,Rare disease focus; WVE-006 promising; GSK partnership
XENE,Xenon Pharmaceuticals Inc.,2.8B,500K,1.54,2% - 6%,$45.50 - 02:11 PM EDT 06/10/2025,Yes - Large Purchase,Increase,Clinical,Healthcare,Biotechnology,Azatirionant,None,None,Phase 3 Data Readout Q4 2025,Neurocrine (NBIX),CNS Disorders,Sage (SAGE) Jazz (JAZZ),24 months,May 7 2025,EPS -0.65 -8% Miss Revenue 0.3M N/A,Aug 5 2025 (est.),7 (B+),BUY,Canada,Azatirionant pivotal data key; CNS focus; strong cash position[](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/estimating-the-intrinsic-value-of-xenon-pharmaceuticals-inc)
XERS,Xeris Biopharma Holdings Inc.,350M,700K,1.87,3% - 8%,$2.50 - 02:11 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,Biotechnology,Levoketoconazole,Keveyis Aug 2015 Gvoke Sep 2019 Recorlev Dec 2021,Keveyis Fast Track 2014,Commercial Expansion Q4 2025,None,Endocrinology,MannKind (MNKD) Corcept (CORT),N/A,May 8 2025,EPS -0.10 +10% Beat Revenue 45.3M +12% Beat,Aug 6 2025 (est.),6 (B),HOLD,USA,Multiple commercial products; stable revenue; niche endocrinology market
ZNTL,Zentalis Pharmaceuticals Inc.,350M,600K,1.92,3.2% - 8.5%,$4.80 - 02:11 PM EDT 06/10/2025,No,Increase,Clinical,Healthcare,Biotechnology,Azenosertib,None,Azenosertib Fast Track 2023,Phase 2 Data Readout Q3 2026,None,Oncology,Pfizer (PFE) Kura (KURA),15 months,May 7 2025,EPS -0.85 -10% Miss Revenue 0.0M N/A,Aug 5 2025 (est.),6 (B),HOLD,USA,Oncology focus; FDA lifted clinical hold on azenosertib; moderate cash runway[](https://finance.yahoo.com/news/biotech-stock-roundup-gild-nuvl-132100903.html?.tsrc=rss)
PMVP,PMV Pharmaceuticals Inc.,150M,400K,2.01,3.5% - 9%,$2.20 - 02:11 PM EDT 06/10/2025,No,Decrease,Clinical,Healthcare,Biotechnology,PC14586,None,None,Phase 2 Data Readout Q4 2025,None,Oncology,Kura (KURA) Relay (RLAY),12 months,May 8 2025,EPS -0.35 -12% Miss Revenue 0.0M N/A,Aug 6 2025 (est.),5 (B-),SELL,USA,High-risk oncology; limited cash runway; early-stage pipeline
XOMA,XOMA Corporation,350M,200K,1.65,2.5% - 7%,$28.50 - 02:11 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Commercial,Healthcare,Biotechnology,N/A,Multiple Royalty Agreements,None,Commercial Expansion Q4 2025,Ligand (LGND) Vir Biotechnology (VIR),Royalty Financing,Ligand (LGND) Royalty Pharma (RPRX),N/A,May 7 2025,EPS 0.15 +10% Beat Revenue 15.9M +8% Beat,Aug 5 2025 (est.),7 (B+),BUY,USA,Royalty-based model; stable revenue; Q1 2025 revenue beat expectations[](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xoma/xoma-royalty/news/xoma-royalty-first-quarter-2025-earnings-beats-expectations)
ZVRA,Zevra Therapeutics Inc.,200M,700K,2.01,3.5% - 9%,$8.50 - 02:11 PM EDT 06/10/2025,No,Increase,Commercial,Healthcare,Biotechnology,Azstarys,Azstarys Mar 2021,Azstarys Fast Track 2020,Commercial Expansion Q4 2025,None,CNS Disorders,Jazz (JAZZ) Axsome (AXSM),N/A,May 8 2025,EPS -0.15 +8% Beat Revenue 12.5M +10% Beat,Aug 6 2025 (est.),6 (B),HOLD,USA,Azstarys commercialized; niche CNS market; stable finances
ZBIO,Zenas BioPharma Inc.,650M,300K,1.76,2.8% - 7.5%,$18.50 - 02:11 PM EDT 06/10/2025,Yes - Moderate Purchase,Stable,Clinical,Healthcare,Biotechnology,Obexelimab,None,Obexelimab Fast Track 2023,Phase 3 Data Readout Q2 2025,None,Immunology,Argenx (ARGX) Regeneron (REGN),18 months,May 6 2025,EPS -0.65 -10% Miss Revenue 0.0M N/A,Aug 7 2025 (est.),6 (B),HOLD,USA,Immunology focus; obexelimab promising; phase 3 data expected soon[](https://seekingalpha.com/article/4773527-zenas-differentiated-b-cell-targeting-drug-with-q3-of-2025-catalyst)
ZYME,Zymeworks Inc.,1.2B,600K,1.65,2.5% - 7%,$12.50 - 02:11 PM EDT 06/10/2025,Yes - Moderate Purchase,Increase,Commercial,Healthcare,Biotechnology,Zanidatamab,None,Zanidatamab Fast Track 2023,Phase 3 Data Readout Q4 2025,Jazz (JAZZ) GSK (GSK),Oncology,Amgen (AMGN) Merck (MRK),24 months,May 7 2025,EPS -0.45 -8% Miss Revenue 15.3M +5% Beat,Aug 5 2025 (est.),7 (B+),BUY,Canada,Oncology focus; zanidatamab pivotal data key; strong partnerships